

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	IMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	BEILSTEIN updated with new compounds
NEWS	12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	13	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	14	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	16	AUG 27	USPATOLD now available on STN
NEWS	17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	19	SEP 13	FORIS renamed to SOFIS
NEWS	20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	21	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	22	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	23	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	24	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS EXPRESS	19	SEPTEMBER 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:20:50 ON 17 OCT 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:20:59 ON 17 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 OCT 2007 HIGHEST RN 950817-67-1

DICTIONARY FILE UPDATES: 16 OCT 2007 HIGHEST RN 950817-67-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10596561.str



chain nodes :

10 11 12 13 14 22

ring nodes :

1 2 3 4 5 6 7 8 9 15 16 17 18 19 20

chain bonds :

3-22 6-10 7-11 11-12 11-13 12-14 14-15

ring bonds :
 1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9 15-16 15-20 16-17 17-18 18-19
 19-20
 exact/norm bonds :
 1-2 1-5 2-3 6-10 11-12 11-13 12-14
 exact bonds :
 3-4 3-22 7-11 14-15
 normalized bonds :
 4-5 4-6 5-9 6-7 7-8 8-9 15-16 15-20 16-17 17-18 18-19 19-20
 isolated ring systems :
 containing 1 : 15 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 22:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 09:21:22 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 58 TO ITERATE

100.0% PROCESSED. 58 ITERATIONS

SEARCH TIME: 00.00.01

42 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 704 TO 1616


PROJECTED ANSWERS: 451 TO 1227

L2 42 SEA SSS SAM L1

=> d scan

L2 42 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-
MF C23 H29 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 11 full

FULL SEARCH INITIATED 09:22:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1176 TO ITERATE

100.0% PROCESSED 1176 ITERATIONS
SEARCH TIME: 00.00.01

907 ANSWERS

L3 907 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
172.55	172.76

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 09:22:09 ON 17 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Oct 2007 VOL 147 ISS 17

FILE LAST UPDATED: 16 Oct 2007 (20071016/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full

L4 14 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1042249 CAPLUS

DOCUMENT NUMBER: 143:347166

TITLE: Preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors

INVENTOR(S): Cook, Caroline Mary; Dowle, Michael Dennis; Edlin, Christopher David; Johnson, Martin Redpath; Jones, Paul Spencer; Lindvall, Mika Kristian; Trivedi, Naimisha; Redgrave, Alison Judith

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 142 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090354	A1	20050929	WO 2005-GB987	20050315
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1740590	A1	20070110	EP 2005-718039	20050315
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV			
PRIORITY APPLN. INFO.:			GB 2004-5893	A 20040316
			GB 2005-5214	A 20050314
			WO 2005-GB987	W 20050315
OTHER SOURCE(S):	MARPAT 143:347166			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [R1 = alkyl, fluoroalkyl, CH₂CH₂OH; R2 = H, Me, fluoroalkyl; R3 = (un)substituted 4-(aminocarbonyl)cyclohexyl, N-aminocarbonylpiperidinyl, N-aminocarbonylpyrrolidinyl; R4 = H; R5 = II-V (wherein one or two of A, B, D, E and F = N, and the remaining of A-F are CH, CR₆; R6 = halo, alkyl, fluoroalkyl, etc.; n = 0-2; G = O, S, NR₉; R9 = H, alkyl, fluoroalkyl; none, one, two or three of J, L, M and Q = N, and

the remaining of J-Q = CH, CR6; r = 0-2; m = 1-2)] that are inhibitors of phosphodiesterase type IV (PDE4) useful in the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, allergic rhinitis, psoriasis or atopic dermatitis in a mammal such as a human, were prepared and formulated. Thus, amidation of the corresponding acid (preparation given) with 2,4-dimethylbenzylamine afforded VI which showed pIC50 of 9.1-9.2 (\pm about 0.5) against PDE4B. Preps. of the pharmaceutical comps. (including micronization example) comprising the compds. I were described:


IT 865713-86-6P 865713-87-7P 865718-02-1P
 865718-03-2P 865718-04-3P 865718-05-4P
 865718-06-5P 865718-07-6P 865718-08-7P
 865718-09-8P 865718-10-1P 865718-11-2P
 865718-12-3P 865718-13-4P 865718-14-5P
 865718-15-6P 865718-16-7P 865718-17-8P
 865718-19-0P 865718-20-3P 865718-21-4P
 865718-22-5P 865718-23-6P 865718-24-7P
 865718-25-8P 865718-26-9P 865718-27-0P
 865718-28-1P 865718-29-2P 865718-30-5P
 865718-31-6P 865718-32-7P 865718-33-8P
 865718-34-9P 865718-35-0P 865718-36-1P
 865718-38-3P 865718-39-4P 865718-40-7P
 865718-41-8P 865718-42-9P 865718-43-0P
 865718-44-1P 865718-45-2P 865718-46-3P
 865718-47-4P 865718-48-5P 865718-49-6P
 865718-50-9P 865718-51-0P 865718-52-1P
 865718-53-2P 865718-54-3P 865718-55-4P
 865718-56-5P 865718-57-6P 865718-58-7P
 865718-59-8P 865718-61-2P 865718-62-3P
 865718-63-4P 865718-64-5P 865718-65-6P
 865718-67-8P 865718-68-9P 865718-69-0P
 865718-70-3P 865718-71-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase type 4 (PDE4) inhibitors for treating inflammatory and allergic diseases)


RN 865713-86-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl- (CA INDEX NAME)



RN 865713-87-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 865718-02-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(2,4-dimethylphenyl)methyl]-1-ethyl- (CA INDEX NAME)



RN 865718-03-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)






RN 865718-06-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-
(CA INDEX NAME)


Relative stereochemistry.



RN 865718-07-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[trans-4-(aminocarbonyl)cyclohexyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-
(CA INDEX NAME)

Relative stereochemistry.




RN 865718-08-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(2,4-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-09-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 865718-10-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(4-hydroxyphenyl)methyl]- (CA INDEX NAME)




RN 865718-11-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 865718-12-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[2-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 865718-13-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(3-hydroxyphenyl)methyl]- (CA INDEX NAME)




RN 865718-14-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(2,3-dichlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-15-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(2,3-dimethylphenyl)methyl]-1-ethyl- (CA INDEX NAME)



RN 865718-16-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-([1,1'-biphenyl]-2-ylmethyl)-1-ethyl- (CA INDEX NAME)




RN 865718-17-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(4-chloro-2-fluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-19-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[[4-(difluoromethoxy)phenyl]methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-20-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-((4-chloro-2-methylphenyl)methyl)piperidinyl]amino]-N-[[4-(difluoromethoxy)phenyl]methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-21-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-22-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[4-(methanesulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 865718-23-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]- (CA INDEX NAME)




RN 865718-24-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(4-chlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-25-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-([1,1'-biphenyl]-4-ylmethyl)-1-ethyl- (CA INDEX NAME)




RN 865718-26-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-([4'-ethoxy[1,1'-biphenyl]-4-yl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-27-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-([1,1'-biphenyl]-3-ylmethyl)-1-ethyl- (CA INDEX NAME)




RN 865718-28-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 865718-29-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)




RN 865718-30-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)




RN 865718-31-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-32-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-33-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(4'-methyl[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)




RN 865718-34-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)




RN 865718-35-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[2-(3-furanyl)phenyl]methyl]- (CA INDEX NAME)




RN 865718-36-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[2-(6-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 865718-38-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[2-(3-thienyl)phenyl]methyl]- (CA INDEX NAME)




RN 865718-39-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[2-(4-methyl-3-thienyl)phenyl]methyl]- (CA INDEX NAME)




RN 865718-40-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(5-methyl[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)




RN 865718-41-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[4-methyl-2-(3-thienyl)phenyl]methyl]- (CA INDEX NAME)




RN 865718-42-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[2-(3-furanyl)-4-methylphenyl]methyl]- (CA INDEX NAME)



RN 865718-43-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3'-chloro-5-methyl[1,1'-biphenyl]-2-yl)methyl]-1-ethyl- (CA INDEX NAME)



RN 865718-44-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-N-[(2,4-dimethylphenyl)methyl]-1-ethyl-
(CA INDEX NAME)


Relative stereochemistry.



RN 865718-45-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[trans-4-(aminocarbonyl)cyclohexyl]amino]-N-[(2,4-dimethylphenyl)methyl]-1-ethyl-
(CA INDEX NAME)


Relative stereochemistry.



RN 865718-46-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 865718-47-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 865718-48-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(2,3-dimethylphenyl)methyl]-1-ethyl-
(CA INDEX NAME)




RN 865718-49-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-([1,1'-biphenyl]-2-ylmethyl)-1-ethyl-
(CA INDEX NAME)




RN 865718-50-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(4-chloro-2-fluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-51-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(2,3-dichlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)



RN 865718-52-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[[2-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 865718-53-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(4-chlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-54-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 865718-55-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-([1,1'-biphenyl]-4-ylmethyl)-1-ethyl- (CA INDEX NAME)




RN 865718-56-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(4-hydroxyphenyl)methyl]- (CA INDEX NAME)




RN 865718-57-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 865718-58-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(2,4-difluorophenyl)methyl]-1-ethyl-
(CA INDEX NAME)




RN 865718-59-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[[4-(difluoromethoxy)phenyl]methyl]-1-ethyl-
(CA INDEX NAME)




RN 865718-61-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-([1,1'-biphenyl]-3-ylmethyl)-1-ethyl- (CA INDEX NAME)




RN 865718-62-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(4-fluorophenyl)methyl]- (CA INDEX NAME)




RN 865718-63-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(4-chloro-2-methylphenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-64-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-65-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[[2,3-dichloro-6-(hydroxymethyl)phenyl]methyl]-1-ethyl- (CA INDEX NAME)



RN 865718-67-8 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(3,4-dimethoxyphenyl)methyl]-1-ethyl- (CA INDEX NAME)



RN 865718-68-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(2,4-dimethylphenyl)methyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865718-69-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 865718-70-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(3R)-1-(aminocarbonyl)-3-

pyrrolidinyl]amino]-N-[(2,4-dimethylphenyl)methyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865718-71-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




IT 865718-73-6P 865718-74-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase type 4 (PDE4) inhibitors for treating inflammatory and allergic diseases)

RN 865718-73-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(2-bromophenyl)methyl]-1-ethyl- (CA INDEX NAME)






RN 865718-74-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(2-bromo-4-methylphenyl)methyl]-1-ethyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1042248 CAPLUS
 DOCUMENT NUMBER: 143:347165
 TITLE: Preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase type 4 (PDE4) inhibitors
 INVENTOR(S): Coe, Diane Mary; Cook, Caroline Mary; Cooper, Anthony William James; Edlin, Christopher David; Hamblin, Julie Nicole; Johnson, Martin Redpath; Jones, Paul Spencer; Lindvall, Mika Kristian; Mitchell, Charlotte Jane; Redgrave, Alison Judith; Robinson, John Edward
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 114 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090353	A1	20050929	WO 2005-GB976	20050315
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1735315	A1	20061227	EP 2005-718029	20050315
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV			
US 2007167485	A1	20070719	US 2006-598944	20060915
PRIORITY APPLN. INFO.:			GB 2004-5937	A 20040316
			WO 2005-GB976	W 20050315
OTHER SOURCE(S):	MARPAT 143:347165			
GI				



- AB The title compds. I [R1 = Et, Pr, iso-Pr, fluoroalkyl, CH2CH2OH; R2 = H, Me, Et, etc.; NHR3 = NHCR3aR3bCR3cR3dR3e (wherein R3a = Me, Et; R3b, R3c, R3d = H, Me, Et; R3e = H, Me; with provisions); R5 = alkyl, (un)substituted cycloalkyl, (CH2)ncycloalkyl, etc.], useful as inhibitors of phosphodiesterase type IV (PDE4), and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis or allergic rhinitis, were prepared and formulated. Thus, amidation of the acid (1S)-II (preparation given) with 2-ethylbutylamine afforded (1S)-III which showed PDE4B inhibitory activity with pIC50 of 8.1 (± about 0.5).
- IT 865708-81-2P 865708-83-4P 865708-85-6P
865708-86-7P 865708-89-0P 865708-90-3P
865708-92-5P 865708-93-6P 865708-95-8P

865708-96-9P 865708-97-0P 865708-98-1P
 865708-99-2P 865709-01-9P 865709-02-0P
 865709-03-1P 865709-04-2P 865709-05-3P
 865709-06-4P 865709-07-5P 865709-08-6P
 865709-09-7P 865709-11-1P 865709-12-2P
 865709-13-3P 865709-14-4P 865709-15-5P
 865709-17-7P 865709-18-8P 865709-25-7P
 865709-27-9P 865709-29-1P 865709-31-5P
 865709-33-7P 865709-35-9P 865709-36-0P
 865709-37-1P 865709-38-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase type 4 (PDE4)
 inhibitors for treating inflammatory and allergic diseases)

RN 865708-81-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(1R)-1,2-
 dimethylpropyl]amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-83-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(1R)-1,2-
 dimethylpropyl]amino]-1-ethyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA
 INDEX NAME)


Absolute stereochemistry..



RN 865708-85-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(1R)-1,2-
 dimethylpropyl]amino]-1-ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]- (CA
 INDEX NAME)


Absolute stereochemistry.



RN 865708-86-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(difluoromethoxy)phenyl]methyl]-4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-89-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-chloro-6-fluorophenyl)methyl]-4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-90-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[1-[4-(methylsulfonyl)phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-92-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[3-[(methylamino) carbonyl]phenyl]methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-93-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[(1R)-1-phenylpropyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-95-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[[2-(dimethylamino)phenyl]methyl]-4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-96-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[(4-fluorophenyl)methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-97-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-N-(diphenylmethyl)-1-ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-98-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[4-[(methylamino)carbonyl]phenyl]methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-99-2 CAPLUS

CN Benzoic acid, 4-[[[4-[(1S)-1,2-dimethylpropylamino]-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-01-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[4-[(1S)-1,2-dimethylpropylamino]-1-ethyl-N-[(4-hydroxyphenyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-02-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[4-[(1S)-1,2-dimethylpropylamino]-1-ethyl-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-03-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-04-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-difluorophenyl)methyl]-4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-05-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,6-difluorophenyl)methyl]-4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-06-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-07-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,5-difluorophenyl)methyl]-4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-08-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[(3-fluorophenyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-09-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-11-1 CAPLUS

CN Benzoic acid, 3-[[[4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-12-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[[2-(aminocarbonyl)phenyl]methyl]-4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-13-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-14-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[3-[(methylsulfonyl)amino]phenyl]methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-15-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[4-(trifluoromethyl)phenyl]methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-17-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-18-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-(phenylmethyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-25-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[3-(methylsulfonyl)phenyl]methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-27-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-(aminocarbonyl)phenyl]methyl]-4-[(1S)-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-29-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-[(dimethylamino)sulfonyl]phenyl]methyl]-4-[(1S)-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 865709-31-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1,1-dimethylethyl)amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 865709-33-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1,1-dimethylethyl)amino]-1-ethyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 865709-35-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1,1-dimethylethyl)amino]-1-ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)



RN 865709-36-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[[(1R)-1-methylpropyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-37-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[[(1S)-1-methylpropyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 865709-38-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(1-methylpropyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1042247 CAPLUS

DOCUMENT NUMBER: 143:347164

TITLE: Preparation of 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide as a PDE4 inhibitor

INVENTOR(S): Christensen, Siegfried Benjamin, IV; Cook, Caroline Mary; Edlin, Christopher David; Johnson, Martin Redpath; Jones, Paul Spencer; Lindvall, Mika Kristian; Sayani, Aryn Pyarali; Trivedi, Naimisha; Trottet, Lionel

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 90 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090352	A1	20050929	WO 2005-EP3038	20050315
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,			

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG


AU 2005223351	A1	20050929	AU 2005-223351	20050315
CA 2559629	A1	20050929	CA 2005-2559629	20050315
EP 1735314	A1	20061227	EP 2005-716291	20050315

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV

BR 2005008843	A	20070828	BR 2005-8843	20050315
MX 2006PA10486	A	20061208	MX 2006-PA10486	20060914
IN 2006KN02753	A	20070601	IN 2006-KN2753	20060920
NO 2006004450	A	20061114	NO 2006-4450	20061002

PRIORITY APPLN. INFO.: GB 2004-5893 A 20040316
GB 2005-5214 A 20050314
WO 2005-EP3038 W 20050315

OTHER SOURCE(S): MARPAT 143:347164
GI



AB The invention provides 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (I) or a salt thereof which is useful as an inhibitor of phosphodiesterase type IV (PDE4), for example in the treatment and/or prophylaxis of an inflammatory and/or allergic disease, cognitive impairment or depression in a mammal. E.g., a multi-step synthesis of I, starting from 5-amino-1-ethylpyrazole and di-Et ethoxymethylenemalonate, was given. The compound I was tested in various tests (data given). In particular, the invention provides the use of the compound I or its pharmaceutically acceptable salt in the treatment and/or prophylaxis of atopic dermatitis in a mammal, for example by external topical administration to the mammal such as a human. Pharmaceutical compns. containing said compound or salt, in particular suitable for external topical administration, are also provided and claimed.


IT 865713-86-6P 865713-87-7P 865713-89-9P
865713-90-2P 865713-91-3P 865713-92-4P
865713-93-5P 865713-94-6P 865713-95-7P
865713-96-8P 865713-97-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[3,4-b]pyridine derivative as phosphodiesterase type 4 (PDE4) inhibitor for treating inflammatory and allergic diseases)


RN 865713-86-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl- (CA INDEX NAME)



RN 865713-87-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 865713-89-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, monohydrobromide (9CI) (CA INDEX NAME)




● HBr

RN 865713-90-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, sulfate (1:1)
 (CA INDEX NAME)


CM 1

CRN 865713-86-6
 CMF C24 H31 N7 O2



CM 2


CRN 7664-93-9
 CMF H2 O4 S



RN 865713-91-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, mononitrate (9CI) (CA INDEX NAME)


CM 1

CRN 865713-86-6
 CMF C24 H31 N7 O2



CM 2


CRN 7697-37-2
 CMF H N O3



RN 865713-92-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, phosphate (1:1) (CA INDEX NAME)

CM 1


CRN 865713-86-6
 CMF C24 H31 N7 O2



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 865713-93-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 865713-86-6


CMF C24 H31 N7 O2



CM 2

CRN 104-15-4

CMF C7 H8 O3 S




RN 865713-94-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 865713-86-6


CMF C24 H31 N7 O2



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 865713-95-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 865713-86-6
CMF C24 H31 N7 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 865713-96-8 CAPLUS

CN Ethanesulfonic acid, compd. with 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (1:1) (CA INDEX NAME)

CM 1


CRN 865713-86-6
CMF C24 H31 N7 O2



CM 2

CRN 594-45-6

CMF C2 H6 O3 S




RN 865713-97-9 CAPLUS

CN Naphthalenesulfonic acid, compd. with 4-[[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 865713-86-6

CMF C24 H31 N7 O2



CM 2

CRN 25155-19-5
CMF C10 H8 O3 S
CCI IDS



D1-SO₃H

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1042245 CAPLUS

DOCUMENT NUMBER: 143:347163

TITLE: Preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase type 4 (PDE4) inhibitors

INVENTOR(S): Allen, David George; Coe, Diane Mary; Cook, Caroline Mary; Dowle, Michael Dennis; Edlin, Christopher David; Hamblin, Julie Nicole; Johnson, Martin Redpath; Jones, Paul Spencer; Lindvall, Mika Kristian; Mitchell, Charlotte Jane; Redgrave, Alison Judith; Trivedi, Naimisha

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090348	A1	20050929	WO 2005-GB983	20050315
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1751151	A1	20070214	EP 2005-718036	20050315
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV			
PRIORITY APPLN. INFO.:			GB 2004-5933	A 20040316
			WO 2005-GB983	W 20050315
OTHER SOURCE(S):	MARPAT 143:347163			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [W = Ar, CR4R5Ar, II, III (wherein Ar = IV, V; m = 1-2); R1 = alkyl, fluoroalkyl or CH₂CH₂OH; R2 = alkyl, cycloalkyl or (CH₂)_ncycloalkyl (n = 1-2); R3 = (un)substituted cycloalkyl, mono-unsatd. cycloalkenyl, heterocyclyl, etc.; R4, R5 = H, Me, Et, cyclopropyl, etc.; A, B, D, E, F = CR6, N or nitrogen-oxide (with provisions); R6 = H, halo, alkyl, etc.; G = O, S, NR9 (R9 = H, alkyl, fluoroalkyl); J, L, M, Q = CR7, C, N (with provisions); R7 = H, halo, alkyl, etc.], useful as inhibitors of phosphodiesterase type IV (PDE4), and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis or allergic rhinitis, were prepared and formulated. E.g., a multi-step synthesis of VI, starting from di-Et malonate and cyclopropylcarbonyl chloride, was given. All of the exemplified compds. I showed PDE4B inhibitory activities in the range of pIC₅₀ = about 7 (± about 0.5) to about 9 (± about 0.5).


IT 865713-31-1P 865713-32-2P 865713-33-3P
865713-34-4P 865713-35-5P 865713-36-6P
865713-37-7P 865713-38-8P 865713-39-9P
865713-40-2P 865713-42-4P 865713-43-5P
865713-44-6P 865713-46-8P 865713-47-9P
865713-48-0P 865713-49-1P 865713-51-5P
865713-52-6P 865713-53-7P 865713-54-8P
865713-55-9P 865713-57-1P 865713-58-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase type 4 (PDE4) inhibitors for treating inflammatory and allergic diseases)


RN 865713-31-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-chloro-2-methylphenyl)methyl]-6-cyclopropyl-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-32-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 6-cyclopropyl-1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-33-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 6-cyclopropyl-1-ethyl-N-[(4-methoxyphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-34-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 6-cyclopropyl-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-35-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-6-cyclopropyl-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-36-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-6-cyclopropyl-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-37-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-6-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-38-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-methoxyphenyl)methyl]-6-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-39-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-chloro-2-methylphenyl)methyl]-1-ethyl-6-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-40-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethylphenyl)methyl]-1-ethyl-6-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-42-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1,6-diethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-43-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1,6-diethyl-N-[(4-methoxyphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-44-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethylphenyl)methyl]-1,6-diethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-46-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-1,6-diethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-47-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 6-cyclobutyl-1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-48-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 6-cyclobutyl-1-ethyl-N-[(4-methoxyphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-49-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 6-cyclobutyl-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-51-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-chloro-2-methylphenyl)methyl]-6-cyclobutyl-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-52-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-6-cyclobutyl-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-53-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-6-cyclobutyl-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-54-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 6-(cyclopropylmethyl)-1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-55-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 6-(cyclopropylmethyl)-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-57-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-6-(cyclopropylmethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 865713-58-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 6-cyclopentyl-1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

(L4 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:570893 CAPLUS

DOCUMENT NUMBER: 143:97353

TITLE: Preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase, especially PDE4B, inhibitors for treatment of inflammatory and/or allergic diseases

INVENTOR(S): Allen, David George; Coe, Diane Mary; Cook, Caroline Mary; Dowle, Michael Dennis; Edlin, Christopher David; Hamblin, Julie Nicole; Johnson, Martin Redpath; Jones, Paul Spencer; Lindvall, Mika Kristian; Mitchell, Charlotte Jane; Redgrave, Alison Judith; Robinson, John Edward; Trivedi, Naimisha

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 295 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058892	A1	20050630	WO 2004-EP14490	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				


CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG
 WO 2004056823 A1 20040708 WO 2003-EP314867 20031219
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
 GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
 OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2004299277 A1 20050630 AU 2004-299277 20041217
 CA 2557004 A1 20050630 CA 2004-2557004 20041217
 EP 1737857 A1 20070103 EP 2004-804089 20041217
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV
 CN 1914205 A 20070214 CN 2004-80041657 20041217
 JP 2007514704 T 20070607 JP 2006-544380 20041217
 US 20071111995 A1 20070517 US 2006-596561 20060616
 NO 2006003340 A 20060912 NO 2006-3340 20060718
 PRIORITY APPLN. INFO.: WO 2003-EP314867 A 20031219
 GB 2004-5899 A 20040316
 GB 2004-5936 A 20040316
 GB 2004-6754 A 20040325
 GB 2002-30045 A 20021223
 GB 2002-30165 A 20021224
 GB 2003-7998 A 20030407
 WO 2003-EP14867 A 20031219
 WO 2004-EP14490 W 20041217
 OTHER SOURCE(S): MARPAT 143:97353
 GI



I




II




III

- AB Title compds. I [wherein Ar = (un)substituted Ph, naphthyl, indanyl, pyridinyl, etc. with provisos; R1 = fluoro/alkyl, CH₂CH₂OH; R2 = H, Me, fluoroalkyl; R3 = (un)substituted cycloalkyl, monounsaturated cycloalkenyl, bicycyl, heterocyclyl; R4 = H, Me, Et, Pr, i-Pr, fluoroalkyl, cyclopropyl, etc.; R5 = H, fluoro/alkyl, (un)substituted cyclo/alkyl, Ph, etc.; provided that at least one of R4 and R5 is not H; and salts thereof] were prepared as selective phosphodiesterase 4 (PDE4), especially PDE4B, inhibitors. The invention also provides for the use of I for the treatment and/or prophylaxis of an inflammatory and/or allergic disease, such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, allergic rhinitis or atopic dermatitis. Eight biol. methods are given. For example, coupling of acid II with 2-phenyl-2-propanamine gave title compound III. Selected I inhibited PDE4B with IC₅₀ in the range of. I are in particle size-reduced form (DC₅₀ value of about 0.5 to about 10 μ) when used in inhalant compns.
- IT 856560-57-1P, 1-Ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-63-9P, N-[1-(3,5-Dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses) (PDE4B inhibitor; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)
- RN 856560-57-1 CAPLUS
- CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 856560-63-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




IT 856558-90-2P, N-[1-(4-Chlorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856558-91-3P, 1-Ethyl-N-[1-[4-(ethyloxy)phenyl]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856559-00-7P, N-[1-(4-Chlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-99-1P, 1-Ethyl-N-[1-[4-[(1-methylethyl)oxy]phenyl]ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-56-3P, 1-Ethyl-4-[(3-hydroxycyclohexyl)amino]-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(PDE4B inhibitor; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)


RN 856558-90-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-91-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-ethoxyphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-00-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856560-99-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-[4-(1-methylethoxy)phenyl]ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 856561-56-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(3-hydroxycyclohexyl)amino]-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 856561-70-1P 856561-71-2P 856561-72-3P

856561-73-4P 856561-74-5P 856561-75-6P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(PDE4B inhibitor; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)

RN 856561-70-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 856561-71-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 856561-72-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-[4-(1-methylethoxy)phenyl]ethyl]-4-[(4-oxocyclohexyl)amino]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 856561-73-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-[4-(1-methylethoxy)phenyl]ethyl]-4-[(4-oxocyclohexyl)amino]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 856561-74-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 856561-75-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-, (-)- (CA INDEX NAME)

Rotation (-).



IT 856561-62-1P 856561-63-2P 856561-64-3P

856561-65-4P 856561-66-5P 856561-67-6P

856561-69-8P 856561-77-8P 856561-78-9P,

1-Ethyl-4-[(1S,3R)-3-hydroxycyclohexylamino]-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-79-0P, 1-Ethyl-4-[(1R,3S)-3-hydroxycyclohexylamino]-N-

[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); USES (Uses)


(PDE4B inhibitor; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors

for treatment of inflammatory and/or allergic diseases)

RN 856561-62-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 856561-63-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 856561-64-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 856561-65-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 856561-66-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-ethoxyphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 856561-67-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-ethoxyphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 856561-69-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1S)-1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-77-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1S)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-78-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[[(1S,3R)-3-hydroxycyclohexyl]amino]-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 856561-79-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[[(1R,3S)-3-hydroxycyclohexyl]amino]-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




- IT 856560-51-5P, N-[1-(4-Chlorophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856560-52-6P, N-[1-(4-Chlorophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856560-55-9P, 1-Ethyl-N-[1-[4-(ethyloxy)phenyl]ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856560-56-0P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-[4-(propyloxy)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856560-58-2P, 1-Ethyl-N-[(1R)-2-hydroxy-1-phenylethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856560-59-3P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-(1-phenylpropyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856560-61-7P, 1-Ethyl-N-[1-[4-(1-methylethyl)phenyl]ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856560-64-0P, 1-Ethyl-N-[(1R)-1-[4-(methyloxy)phenyl]ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856560-65-1P, 1-Ethyl-N-[1-(4-fluorophenyl)propyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856560-66-2P, N-[1-(2,3-Dichlorophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856560-67-3P, 1-Ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856560-68-4P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-(1-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-69-5P, N-[(1R)-1-(4-Bromophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-79-7P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[(1R)-1-phenylpropyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-80-0P, 1-Ethyl-N-[(1R)-1-[3-(methyloxy)phenyl]ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-89-9P, 1-Ethyl-N-[1-(3-hydroxyphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-91-3P, N-[1-(2,3-Dichlorophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(PDE4B inhibitor; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)
RN 856560-51-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-52-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-55-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-ethoxyphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 856560-56-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-(4-propoxyphenyl)ethyl]- (CA INDEX NAME)



RN 856560-58-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-2-hydroxy-1-phenylethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-59-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-(1-phenylpropyl)- (CA INDEX NAME)



RN 856560-61-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-[4-(1-methylethyl)phenyl]ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 856560-64-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methoxyphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-65-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 856560-66-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dichlorophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 856560-67-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856560-68-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-(1-phenylethyl)- (CA INDEX NAME)



RN 856560-69-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-79-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-80-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-methoxyphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-89-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(3-hydroxyphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 856560-91-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dichlorophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



IT 720705-46-4P, 1-Ethyl-N-((1R)-2-hydroxy-1-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 720705-47-5P, 1-Ethyl-N-((1S)-2-hydroxy-1-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 720705-50-0P, 1-Ethyl-N-((1S,2R)-2-hydroxy-1-phenylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856558-81-1P, 1-Ethyl-N-((1R)-1-phenylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856558-82-2P, 1-Ethyl-N-(1-methyl-1-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856558-83-3P, 1-Ethyl-N-[1-[4-(methylsulfonyl)phenyl]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856558-84-4P, N-(Diphenylmethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856558-86-6P,
 1-Ethyl-N-((1S)-1-phenylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856558-87-7P,
 1-Ethyl-N-((1S)-1-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856558-88-8P,
 1-Ethyl-N-((1R)-1-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856558-92-4P,
 1-Ethyl-N-(3-hydroxy-1-phenylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856558-93-5P,
 1-Ethyl-N-[1-(3-hydroxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856558-94-6P,
 N-[2-(Dimethylamino)-1-phenylethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-

yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856558-95-7P,
1-Ethyl-N-[1-phenyl-2-(1-pyrrolidinyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856558-96-8P,
1-Ethyl-N-[1-(hydroxymethyl)-1-phenylpropyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856558-97-9P,
1-Ethyl-N-[1-[4-(propyloxy)phenyl]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856558-98-0P,
Methyl 3-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-3-phenylpropanoate 856558-99-1P,
1-Ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-01-8P, Ethyl
[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino](phenyl)acetate 856559-02-9P,
1-Ethyl-N-[(1R)-1-[3-(methyloxy)phenyl]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-03-0P,
1-Ethyl-N-[(1S)-2-(methyloxy)-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-04-1P,
N-[(1R)-2-Amino-2-oxo-1-phenylethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-05-2P,
1-Ethyl-N-[(1R)-1-(4-nitrophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-06-3P,
1-Ethyl-N-[(1R)-2-(methyloxy)-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-07-4P,
1-Ethyl-N-(2-hydroxy-1,1-diphenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-08-5P,
N-[1-(3-Cyanophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-09-6P,
N-[Cyano(phenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-10-9P,
N-[Cyclopropyl[4-(methyloxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-12-1P
, N-(1,2-Diphenylethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-13-2P,
1-Ethyl-N-[1-[4-(methyloxy)phenyl]butyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-16-5P,
N-[1-(Aminocarbonyl)-1-phenylpropyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-20-1P,
N-[1-[4-(Cyclohexyloxy)-3-methylphenyl]ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-21-2P,
N-[1-[3-(Cyclohexyloxy)-4-(methyloxy)phenyl]ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-22-3P,
N-[1-(2,3-Dichlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-23-4P,
N-[1-[4-(Cyclohexyloxy)-3-hydroxyphenyl]ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-24-5P,
N-[1-[4-(Cyclopentyloxy)phenyl]ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-25-6P,
1-Ethyl-N-[1-(4-methylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-27-8P,
N-[1-(4-Bromophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-28-9P,
1-Ethyl-N-[(1S)-1-(4-iodophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-29-0P,
N-[1-[4-(Aminosulfonyl)phenyl]ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-30-3P,
1-Ethyl-N-(1-methyl-1-phenylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-37-0P,
1-Ethyl-N-[1-[4-(1-methylethyl)phenyl]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-38-1P,
N-[1-(3,5-Dimethylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-39-2P,
1-Ethyl-N-[(1R)-1-[4-(methyloxy)phenyl]ethyl]-4-[(tetrahydro-2H-pyran-4-

yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-40-5P,
 1-Ethyl-N-[(1S)-1-[4-(methyloxy)phenyl]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-41-6P,
 1-Ethyl-N-(1-phenylhexyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-42-7P,
 1-Ethyl-N-(1-phenylpentyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-43-8P,
 1-Ethyl-N-(2-methyl-1-phenylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-44-9P,
 1-Ethyl-N-(1-phenylbutyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-45-0P,
 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-(2,2,2-trifluoro-1-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-46-1P,
 N-[Cyclopropyl(phenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-47-2P,
 1-Ethyl-N-[1-(4-fluorophenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-48-3P,
 N-[1-(2,3-Dichlorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-49-4P,
 1-Ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-50-7P,
 1-Ethyl-N-(1-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-51-8P,
 N-[(1R)-1-(4-Bromophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-52-9P,
 N-[1-(4-Chlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-53-0P,
 N-[1-(3,4-Dichlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-54-1P
 856559-55-2P 856559-56-3P 856559-57-4P
 856559-58-5P 856559-59-6P 856559-60-9P
 856559-61-0P 856559-62-1P 856559-63-2P
 856559-64-3P 856559-65-4P 856559-66-5P
 856559-67-6P 856559-68-7P 856559-69-8P
 856559-70-1P 856559-71-2P 856559-72-3P
 856559-73-4P 856559-74-5P 856559-75-6P
 856559-76-7P 856559-77-8P 856559-80-3P,
 N-[1-(4-Bromophenyl)-2,2,2-trifluoroethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-81-4P
 , 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[2,2,2-trifluoro-1-[3-(methyloxy)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-82-5P,
 4-(Cyclohexylamino)-1-ethyl-N-[1-[4-(methylsulfonyl)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-83-6P,
 4-(Cyclohexylamino)-1-ethyl-N-[(1R)-1-phenylpropyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-84-7P,
 4-(Cyclohexylamino)-N-(diphenylmethyl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-85-8P,
 4-(Cyclohexylamino)-1-ethyl-N-[(1R)-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-86-9P,
 Ethyl [[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino(phenyl)acetate 856559-87-0P,
 N-[1-(4-Chlorophenyl)ethyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-88-1P,
 4-(Cyclohexylamino)-1-ethyl-N-(1-methyl-1-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-89-2P,
 4-(Cyclohexylamino)-1-ethyl-N-[1-(4-fluorophenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-90-5P,
 N-[1-(4-Chlorophenyl)propyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-91-6P,
 4-(Cyclohexylamino)-N-(1,2-diphenylethyl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-92-7P,
 4-(Cyclohexylamino)-1-ethyl-N-[1-[4-(propyloxy)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-93-8P,
 Methyl 3-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-3-phenylpropanoate 856559-94-9P,
 4-(Cyclohexylamino)-1-ethyl-N-[1-(hydroxymethyl)-1-

phenylpropyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856559-95-0P, 4-(Cyclohexylamino)-1-ethyl-N-(3-hydroxy-1-phenylpropyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856559-96-1P, 4-(Cyclohexylamino)-1-ethyl-N-[1-[4-(ethyloxy)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856559-97-2P, 4-(Cyclohexylamino)-1-ethyl-N-[1-(3-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856559-98-3P, 4-(Cyclohexylamino)-1-ethyl-N-[1-phenyl-2-(1-pyrrolidinyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856559-99-4P, 4-(Cyclohexylamino)-N-[2-(dimethylamino)-1-phenylethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856560-00-4P, 4-(Cyclohexylamino)-1-ethyl-N-[(1R)-2-(methyloxy)-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-01-5P
, N-[(1R)-2-Amino-2-oxo-1-phenylethyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-02-6P,
4-(Cyclohexylamino)-1-ethyl-N-[(1R)-2-hydroxy-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-03-7P,
4-(Cyclohexylamino)-1-ethyl-N-[(1S)-2-hydroxy-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-04-8P,
4-(Cyclohexylamino)-1-ethyl-N-[(1R)-1-[3-(methyloxy)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-05-9P,
4-(Cyclohexylamino)-1-ethyl-N-[(1S)-2-(methyloxy)-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-06-0P,
4-(Cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-nitrophenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-08-2P,
4-(Cyclohexylamino)-1-ethyl-N-[(phenyl)(4-phenyl-1,3-thiazol-2-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-09-3P,
N-[Cyano(phenyl)methyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-11-7P, 4-(Cyclohexylamino)-1-ethyl-N-(2-hydroxy-1,1-diphenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-12-8P, 4-(Cyclohexylamino)-1-ethyl-N-[(1R)-1-[4-(methyloxy)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-13-9P, 4-(Cyclohexylamino)-1-ethyl-N-[1-(4-fluorophenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-14-0P, 4-(Cyclohexylamino)-N-[1-(2,3-dichlorophenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-15-1P, 4-(Cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-16-2P, 4-(Cyclohexylamino)-1-ethyl-N-(1-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-17-3P, N-[(1R)-1-(4-Bromophenyl)ethyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-18-4P, 4-(Cyclohexylamino)-N-[1-(2,3-dichlorophenyl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-19-5P, 4-(Cyclohexylamino)-1-ethyl-N-[1-[3-(methyloxy)phenyl]propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-20-8P, 4-(Cyclohexylamino)-1-ethyl-N-[1-[4-(methyloxy)phenyl]propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-21-9P, N-[1-(4-Bromophenyl)propyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-22-0P, 4-(Cyclohexylamino)-1-ethyl-N-[1-[4-(propyloxy)phenyl]propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-23-1P, 4-(Cyclohexylamino)-N-[1-(3,5-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-24-2P, 4-(Cyclohexylamino)-1-ethyl-N-[1-(4-methylphenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-25-3P, 4-(Cyclohexylamino)-1-ethyl-N-[1-[4-(1-methylethyl)phenyl]propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-26-4P, 4-(Cyclohexylamino)-1-ethyl-N-[1-(2-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-27-5P, 4-(Cyclohexylamino)-N-[1-[4-[(difluoromethyl)oxy]phenyl]ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-28-6P, 4-(Cyclohexylamino)-1-ethyl-N-[1-[4-(trifluoromethyl)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-29-7P, 4-(Cyclohexylamino)-1-ethyl-N-[1-(2-

methylphenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856560-30-0P, 4-(Cyclohexylamino)-1-ethyl-N-[1-[4-(ethyloxy)phenyl]propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856560-31-1P, 4-(Cyclohexylamino)-N-[1-[4-[(difluoromethyl)oxy]phenyl]propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-32-2P, 4-(Cyclohexylamino)-1-ethyl-N-[1-[4-(trifluoromethyl)phenyl]propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856560-33-3P, 4-(Cyclohexylamino)-N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-34-4P, 4-(Cyclohexylamino)-N-[1-(2,3-dimethylphenyl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-35-5P, 4-(Cyclohexylamino)-N-[1-(2,4-dimethylphenyl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-36-6P, N-[1-(4-Chloro-2-fluorophenyl)ethyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-37-7P, N-[1-(3-Chloro-4-methylphenyl)ethyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-38-8P, 4-(Cyclohexylamino)-N-[1-(2,3-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-39-9P, 4-(Cyclohexylamino)-N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-40-2P, N-[1-(4-Chloro-2-fluorophenyl)propyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-41-3P, N-[1-(3-Chloro-4-methylphenyl)propyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-42-4P, 4-(Cyclohexylamino)-1-ethyl-N-[1-(3-hydroxyphenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-43-5P, N-[1-(4-Chlorophenyl)-2-hydroxyethyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-46-8P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-((1S)-1-phenylpropyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-47-9P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-((1R)-1-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-48-0P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-(diphenylmethyl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-49-1P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[1-[4-(methylsulfonyl)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-50-4P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-((1R)-1-phenylpropyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-53-7P, 1-Ethyl-N-[(1S)-1-(4-nitrophenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-54-8P, 1-Ethyl-N-[(1R)-1-(4-nitrophenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-60-6P, (2R)-[[[1-Ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-yl]carbonyl]amino][3-(methyloxy)phenyl]ethanoic acid 856560-62-8P, 1-Ethyl-N-[1-(2-methylphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-70-8P, 1-Ethyl-N-((1S)-2-hydroxy-1-phenylethyl)-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-71-9P, N-[1-(4-Chlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-72-0P, N-[1-[4-[(Difluoromethyl)oxy]phenyl]ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-73-1P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-[4-(trifluoromethyl)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-74-2P, 1-Ethyl-N-[1-(2-methylphenyl)propyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-75-3P, 1-Ethyl-N-[1-[4-(ethyloxy)phenyl]propyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-76-4P, N-[1-[4-[(Difluoromethyl)oxy]phenyl]propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-77-5P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-[4-(trifluoromethyl)phenyl]propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-78-6P, N-[1-(3,4-Dimethylphenyl)propyl]-1-ethyl-4-[(4-

oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-81-1P, N-[1-(2,3-Dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-82-2P, N-[1-(2,4-Dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-83-3P, N-[1-(4-Chloro-2-fluorophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-84-4P, N-[1-(3-Chloro-4-methylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-85-5P
 , N-[1-(2,3-Dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-86-6P,
 N-[1-(2,4-Dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-87-7P,
 N-[1-(4-Chloro-2-fluorophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-88-8P,
 N-[1-(3-Chloro-4-methylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-90-2P,
 1-Ethyl-N-[1-(3-hydroxyphenyl)propyl]-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-92-4P,
 1-Ethyl-N-[1-[3-(methyloxy)phenyl]propyl]-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-93-5P,
 1-Ethyl-N-[1-[4-(methyloxy)phenyl]propyl]-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-94-6P,
 N-[1-(4-Bromophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-95-7P,
 1-Ethyl-4-[(4-oxocyclohexyl) amino]-N-[1-[4-(propyloxy)phenyl]propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-96-8P,
 N-[1-(3,5-Dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-97-9P,
 1-Ethyl-N-[1-(4-methylphenyl)propyl]-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-98-0P,
 1-Ethyl-N-[1-[4-(1-methylethyl)phenyl]propyl]-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-01-8P,
 N-[1-(4-Bromophenyl)-2,2,2-trifluoroethyl]-1-ethyl-4-[(4-oxocyclohexyl) amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-02-9P, 1-Ethyl-4-[(4-oxocyclohexyl) amino]-N-[2,2,2-trifluoro-1-[3-(methyloxy)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-04-1P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl] amino]-N-((1S)-2-hydroxy-1-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-06-3P,
 N-[1-(4-Chlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl] amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-07-4P, 1-Ethyl-N-[1-[4-(ethyloxy)phenyl]ethyl]-4-[[4-(hydroxyimino)cyclohexyl] amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-08-5P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl] amino]-N-[1-[4-(propyloxy)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-09-6P, 1-Ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[[4-(hydroxyimino)cyclohexyl] amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-10-9P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl] amino]-N-((1R)-2-hydroxy-1-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-11-0P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl] amino]-N-(1-phenylpropyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-12-1P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl] amino]-N-[1-[4-(1-methylethyl)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-13-2P, N-[1-(3,5-Dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl] amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-14-3P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl] amino]-N-((1R)-1-[4-(methyloxy)phenyl]ethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-15-4P, 1-Ethyl-N-[1-(4-fluorophenyl)propyl]-4-[[4-(hydroxyimino)cyclohexyl] amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-16-5P, N-[1-(2,3-Dichlorophenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl] amino]-1H-pyrazolo[3,4-b]pyridine-5-

carboxamide 856561-17-6P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-18-7P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-(1-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-19-8P, N-[(1R)-1-(4-Bromophenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-20-1P, N-[1-(2,3-Dichlorophenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-21-2P, N-[1-(4-Chlorophenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-22-3P, N-[1-(4-Chlorophenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-23-4P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(3-(methyloxy)phenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-24-5P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(4-(methyloxy)phenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-25-6P, N-[1-(4-Bromophenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-26-7P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(4-(propyloxy)phenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-27-8P, N-[1-(3,5-Dimethylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-28-9P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(4-methylphenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-29-0P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(4-(1-methylethyl)phenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-30-3P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(2-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-31-4P, N-[1-[4-[(Difluoromethyl)oxy]phenyl]ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-32-5P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(4-(trifluoromethyl)phenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-33-6P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(2-methylphenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-34-7P, 1-Ethyl-N-[1-[4-(ethyloxy)phenyl]propyl]-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-35-8P, N-[1-[4-[(Difluoromethyl)oxy]phenyl]propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-36-9P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(4-(trifluoromethyl)phenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-37-0P, N-[1-(3,4-Dimethylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-38-1P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-phenylpropyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-39-2P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-[3-(methyloxy)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-40-5P, N-[1-(2,3-Dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE4B inhibitor; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)

RN 720705-46-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-2-hydroxy-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 720705-47-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-2-hydroxy-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 720705-50-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S,2R)-2-hydroxy-1-phenylpropyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856558-81-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-phenylpropyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856558-82-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(1-methyl-1-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-83-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-[4-(methylsulfonyl)phenyl]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856558-84-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(diphenylmethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856558-86-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-1-phenylpropyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856558-87-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 856558-88-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 856558-92-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(3-hydroxy-1-phenylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856558-93-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(3-hydroxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-94-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(dimethylamino)-1-phenylethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-95-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-phenyl-2-(1-pyrrolidinyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-96-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(hydroxymethyl)-1-phenylpropyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-97-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-propoxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-98-0 CAPLUS
 CN Benzenepropanoic acid, β -[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 856558-99-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-01-8 CAPLUS
 CN Benzeneacetic acid, α -[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 856559-02-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-methoxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-03-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-2-methoxy-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-04-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-2-amino-2-oxo-1-phenylethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-05-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-nitrophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-06-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-2-methoxy-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-07-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-hydroxy-1,1-diphenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-08-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-cyanophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-09-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(cyanophenylmethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-10-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[cyclopropyl(4-methoxyphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-12-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(1,2-diphenylethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-13-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-methoxyphenyl)butyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-16-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(aminocarbonyl)-1-phenylpropyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-20-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[4-(cyclohexyloxy)-3-methylphenyl]ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-21-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[3-(cyclohexyloxy)-4-methoxyphenyl]ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-22-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dichlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-23-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[4-(cyclohexyloxy)-3-hydroxyphenyl]ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-24-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[4-(cyclopentyloxy)phenyl]ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-25-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-methylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-27-8 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-bromophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-28-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-1-(4-iodophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-29-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[4-(aminosulfonyl)phenyl]ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-30-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(1-methyl-1-phenylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-37-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-[4-(1-methylethyl)phenyl]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-38-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-39-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methoxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-40-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-1-(4-methoxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-41-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(1-phenylhexyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-42-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(1-phenylpentyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-43-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-methyl-1-phenylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-44-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(1-phenylbutyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-45-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-(2,2,2-trifluoro-1-phenylethyl)- (CA INDEX NAME)




RN 856559-46-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(cyclopropylphenylmethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-47-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-48-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dichlorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-49-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856559-50-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(1-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-51-8 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-52-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-53-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,4-dichlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-54-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-methoxyphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-55-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methoxyphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-56-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-57-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-propoxyphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-58-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3,5-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-59-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methylphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-60-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-[4-(1-methylethyl)phenyl]propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-61-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(2-methylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-62-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-[4-(difluoromethoxy)phenyl]ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-63-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-64-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(2-methylphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-65-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-ethoxyphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-66-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-[4-(difluoromethoxy)phenyl]propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-67-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(1R)-1-[4-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-68-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-69-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,3-dimethylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-70-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-71-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chloro-2-fluorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-72-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-methylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-73-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,3-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-74-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-75-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-76-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-methylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-77-8 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-hydroxyphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-80-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-bromophenyl)-2,2,2-trifluoroethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-81-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[2,2,2-trifluoro-1-(3-methoxyphenyl)ethyl]- (CA INDEX NAME)



RN 856559-82-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-[4-(methylsulfonyl)phenyl]ethyl]- (CA INDEX NAME)



RN 856559-83-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856559-84-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-(diphenylmethyl)-1-ethyl- (CA INDEX NAME)



RN 856559-85-8 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-86-9 CAPLUS

CN Benzeneacetic acid, α -[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 856559-87-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 856559-88-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 856559-89-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)




RN 856559-90-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 856559-91-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-(1,2-diphenylethyl)-1-ethyl- (CA INDEX NAME)




RN 856559-92-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-propoxyphenyl)ethyl]- (CA INDEX NAME)




RN 856559-93-8 CAPLUS

CN Benzenepropanoic acid, β -[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-, methyl ester (CA INDEX NAME)




RN 856559-94-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(hydroxymethyl)-1-phenylpropyl]- (CA INDEX NAME)




RN 856559-95-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(3-hydroxy-1-phenylpropyl)- (CA INDEX NAME)




RN 856559-96-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(4-ethoxyphenyl)ethyl]-1-ethyl- (CA INDEX NAME)




RN 856559-97-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(3-hydroxyphenyl)ethyl]- (CA INDEX NAME)




RN 856559-98-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-phenyl-2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 856559-99-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[2-(dimethylamino)-1-phenylethyl]-1-ethyl- (CA INDEX NAME)



RN 856560-00-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-2-methoxy-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-01-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-2-amino-2-oxo-1-phenylethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-02-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-2-hydroxy-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-03-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1S)-2-hydroxy-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-04-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-05-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1S)-2-methoxy-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-06-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-nitrophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-08-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[phenyl(4-phenyl-2-thiazolyl)methyl]- (CA INDEX NAME)




RN 856560-09-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(cyanophenylmethyl)-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)



RN 856560-11-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(2-hydroxy-1,1-diphenylethyl)- (CA INDEX NAME)



RN 856560-12-8 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-13-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-fluorophenyl)propyl]- (CA INDEX NAME)



RN 856560-14-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(2,3-dichlorophenyl)propyl]-1-ethyl- (CA INDEX NAME)



RN 856560-15-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856560-16-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(1-phenylethyl)- (CA INDEX NAME)



RN 856560-17-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)ethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-18-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(2,3-dichlorophenyl)ethyl]-1-ethyl- (CA INDEX NAME)




RN 856560-19-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(3-methoxyphenyl)propyl]- (CA INDEX NAME)




RN 856560-20-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-methoxyphenyl)propyl]- (CA INDEX NAME)




RN 856560-21-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-bromophenyl)propyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 856560-22-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-propoxyphenyl)propyl]- (CA INDEX NAME)




RN 856560-23-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(3,5-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856560-24-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-methylphenyl)propyl]- (CA INDEX NAME)




RN 856560-25-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-[4-(1-methylethyl)phenyl]propyl]- (CA INDEX NAME)




RN 856560-26-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(2-methylphenyl)ethyl]- (CA INDEX NAME)




RN 856560-27-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-[4-(difluoromethoxy)phenyl]ethyl]-1-ethyl- (CA INDEX NAME)




RN 856560-28-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 856560-29-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(2-methylphenyl)propyl]- (CA INDEX NAME)




RN 856560-30-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(4-ethoxyphenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856560-31-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(4-(difluoromethoxy)phenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856560-32-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-(trifluoromethyl)phenyl)propyl]- (CA INDEX NAME)




RN 856560-33-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856560-34-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(2,3-dimethylphenyl)ethyl]-1-ethyl- (CA INDEX NAME)




RN 856560-35-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(2,4-dimethylphenyl)ethyl]-1-ethyl- (CA INDEX NAME)




RN 856560-36-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)ethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)



RN 856560-37-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chloro-4-methylphenyl)ethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 856560-38-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(2,3-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856560-39-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856560-40-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)propyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 856560-41-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chloro-4-methylphenyl)propyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 856560-42-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(3-hydroxyphenyl)propyl]- (CA INDEX NAME)



RN 856560-43-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)-2-hydroxyethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)



RN 856560-46-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-N-[(1S)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-47-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-48-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-(diphenylmethyl)-1-ethyl- (CA INDEX NAME)



RN 856560-49-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-N-[1-[4-(methylsulfonyl)phenyl]ethyl]- (CA INDEX NAME)



RN 856560-50-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-53-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-1-(4-nitrophenyl)ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-54-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-nitrophenyl)ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-60-6 CAPLUS


CN Benzeneacetic acid, α -[[[1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-3-methoxy-, (α R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 856560-62-8 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(2-methylphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 856560-70-8 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-2-hydroxy-1-phenylethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-71-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-72-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[4-(difluoromethoxy)phenyl]ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-73-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 856560-74-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(2-methylphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-75-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-ethoxyphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-76-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[4-(difluoromethoxy)phenyl]propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-77-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-[4-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)




RN 856560-78-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-81-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-82-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-83-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-84-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chloro-4-methylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-85-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-86-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-87-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-88-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chloro-4-methylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-90-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(3-hydroxyphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-92-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(3-methoxyphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-93-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-methoxyphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-94-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-bromophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-95-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-(4-propoxyphenyl)propyl]- (CA INDEX NAME)




RN 856560-96-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethoxyphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-97-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-methylphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-98-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-[4-(1-methylethyl)phenyl]propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856561-01-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-bromophenyl)-2,2,2-trifluoroethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 856561-02-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[2,2,2-trifluoro-1-(3-methoxyphenyl)ethyl]- (CA INDEX NAME)




RN 856561-04-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-


(hydroxyimino)cyclohexyl]amino]-N-[(1S)-2-hydroxy-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856561-06-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)



RN 856561-07-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-ethoxyphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)



RN 856561-08-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-

(hydroxyimino) cyclohexyl] amino]-N-[1-(4-propoxyphenyl) ethyl]- (CA INDEX NAME)



RN 856561-09-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl) ethyl]-4-[[4-(hydroxyimino) cyclohexyl] amino]- (CA INDEX NAME)



RN 856561-10-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino) cyclohexyl] amino]-N-[(1R)-2-hydroxy-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856561-11-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-(1-phenylpropyl)- (CA INDEX NAME)




RN 856561-12-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-[4-(1-methylethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 856561-13-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)



RN 856561-14-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856561-15-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)propyl]-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-16-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dichlorophenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-17-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856561-18-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-(1-phenylethyl)- (CA INDEX NAME)




RN 856561-19-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856561-20-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dichlorophenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-21-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)



RN 856561-22-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)



RN 856561-23-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(3-methoxyphenyl)propyl]- (CA INDEX NAME)

NAME)




RN 856561-24-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino) cyclohexyl] amino]-N-[1-(4-methoxyphenyl)propyl]- (CA INDEX NAME)




RN 856561-25-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-bromophenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino) cyclohexyl] amino]- (CA INDEX NAME)




RN 856561-26-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino) cyclohexyl] amino]-N-[1-(4-propoxyphenyl)propyl]- (CA INDEX NAME).




RN 856561-27-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino) cyclohexyl] amino]- (CA INDEX NAME)




RN 856561-28-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino) cyclohexyl] amino]-N-[1-(4-methylphenyl)propyl]- (CA INDEX NAME)




RN 856561-29-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-[4-(1-methylethyl)phenyl]propyl]-
(CA INDEX NAME)




RN 856561-30-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(2-methylphenyl)ethyl]- (CA INDEX NAME)




RN 856561-31-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[4-(difluoromethoxy)phenyl]ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-
(CA INDEX NAME)




RN 856561-32-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino) cyclohexyl] amino]-N-[1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 856561-33-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino) cyclohexyl] amino]-N-[1-(2-methylphenyl)propyl]- (CA INDEX NAME)



RN 856561-34-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-ethoxyphenyl)propyl]-1-

ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-35-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[4-(difluoromethoxy)phenyl]propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-36-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-[4-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)



RN 856561-37-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)



RN 856561-38-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-39-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856561-40-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)



IT 856561-41-6P, N-[1-(2,4-Dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-42-7P, N-[1-(4-Chloro-2-fluorophenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-43-8P, N-[1-(3-Chloro-4-methylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-44-9P, N-[1-(2,3-Dimethylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-45-0P, N-[1-(2,4-Dimethylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-46-1P, N-[1-(4-Chloro-2-fluorophenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-47-2P, N-[1-(3-Chloro-4-methylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-48-3P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(3-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-49-4P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(3-hydroxyphenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-50-7P 856561-51-8P 856561-52-9P
 856561-53-0P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-[4-[(1-methylethyl)oxy]phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-54-1P 856561-55-2P,
 N-[1-(4-Chlorophenyl)propyl]-1-ethyl-4-[(3-hydroxycyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-57-4P,
 N-[(1R)-1-(2,4-Dimethylphenyl)ethyl]-1-ethyl-4-[(3-hydroxycyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-58-5P, N-[(1S)-1-(2,4-Dimethylphenyl)ethyl]-1-ethyl-4-[(3-hydroxycyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-59-6P, N-[1-(3,4-Dimethylphenyl)propyl]-1-ethyl-4-[(3-hydroxycyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-60-9P, N-[1-(4-Chlorophenyl)propyl]-1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-61-0P, N-[1-(4-Chlorophenyl)ethyl]-1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-68-7P 856561-76-7P 856561-80-3P
 856561-81-4P, 4-[[[1-(Aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-82-5P, 4-[[[1-(Aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-83-6P, 4-[[[1-(Aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-84-7P, 4-[[[1-(Aminocarbonyl)-4-piperidinyl]amino]-N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-85-8P, 4-[[[1-(Aminocarbonyl)-4-piperidinyl]amino]-N-[1-(3-chloro-4-methylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-

carboxamide 856561-86-9P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-N-[1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-87-0P, N-[(1R)-1-(2,5-Dimethylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-88-1P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(1R)-1-(2,4,6-trimethylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-89-2P, 1-Ethyl-N-[(1R)-1-(2-ethylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-90-5P, 1-Ethyl-N-[(1R)-1-(4-ethylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-91-6P, 1-Ethyl-N-[(1R)-1-(4-ethylphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-92-7P, N-[(1R)-1-(2,6-Dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-93-8P, N-[(1R)-1-(2,5-Dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-94-9P, 1-Ethyl-N-[(1R)-1-(2-ethylphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-95-0P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(1R)-1-(2,4,6-trimethylphenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-96-1P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(2,5-dimethylphenyl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-97-2P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(4-ethylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-98-3P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(2-ethylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856561-99-4P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(2,4,6-trimethylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-00-0P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-01-1P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-N-[1-(4-chlorophenyl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-02-2P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-phenylpropyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-03-3P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-N-[1-(4-chlorophenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-04-4P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[1-(4-fluorophenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-05-5P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-06-6P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(4-ethylphenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-07-7P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-[4-(1-methylethyl)phenyl]propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-08-8P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-09-9P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(2,6-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-10-2P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(2,5-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-11-3P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(2-ethylphenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-12-4P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(2,4,6-trimethylphenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-13-5P, 4-[[4-(Aminocarbonyl)cyclohexyl]amino]-N-[1-(4-chlorophenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-14-6P, 4-[[4-(Aminocarbonyl)cyclohexyl]amino]-N-[1-[4-[(difluoromethyl)oxy]phenyl]ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-15-7P, 4-[[4-(Aminocarbonyl)cyclohexyl]amino]-

N-[1-(4-chlorophenyl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-16-8P, 4-[[4-(Aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[1-(4-fluorophenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-17-9P, 4-[[cis-4-(Aminocarbonyl)cyclohexyl]amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-18-0P, 4-[[cis-4-(Aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-19-1P, 4-[[cis-4-(Aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(1R)-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-20-4P, 4-[[cis-4-(Aminocarbonyl)cyclohexyl]amino]-N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-21-5P, 4-[[trans-4-(Aminocarbonyl)cyclohexyl]amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-22-6P, 4-[[trans-4-(Aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-23-7P, 4-[[trans-4-(Aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(1R)-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-24-8P, 4-[[trans-4-(Aminocarbonyl)cyclohexyl]amino]-N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-25-9P, 4-[[[(3S)-1-(Aminocarbonyl)pyrrolidin-3-yl]amino]-N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-26-0P, 4-[[[(3S)-1-(Aminocarbonyl)pyrrolidin-3-yl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-27-1P, 4-[[[(3S)-1-(Aminocarbonyl)pyrrolidin-3-yl]amino]-N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-28-2P, 4-[[[(3S)-1-(Aminocarbonyl)pyrrolidin-3-yl]amino]-N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-29-3P, 4-[[[(3R)-1-(Aminocarbonyl)pyrrolidin-3-yl]amino]-N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-30-6P, 4-[[[(3R)-1-(Aminocarbonyl)pyrrolidin-3-yl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-31-7P, 4-[[[(3R)-1-(Aminocarbonyl)pyrrolidin-3-yl]amino]-N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-32-8P, 4-[[[(3R)-1-(Aminocarbonyl)pyrrolidin-3-yl]amino]-N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-33-9P, 4-[[cis-3-(Aminocarbonyl)cyclobutyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-34-0P, 4-[[cis-3-(Aminocarbonyl)cyclobutyl]amino]-N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-35-1P, 4-[(trans-4-Acetylcyclohexyl)amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-36-2P, 4-[(cis-4-Acetylcyclohexyl)amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-37-3P 856562-38-4P 856562-39-5P 856562-40-8P, N-[4-(Dimethylamino)-1-(3-methylphenyl)-4-oxobutyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-41-9P, 4-[[1-(Aminocarbonyl)-4-piperidinyl]amino]-N-[4-(dimethylamino)-1-(3-methylphenyl)-4-oxobutyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856562-42-0P, 1-Ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-4-[(4-piperidinyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide hydrochloride 856562-43-1P, N-[1-(2,4-Dimethylphenyl)propyl]-1-ethyl-4-[(4-piperidinyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide hydrochloride 856564-62-0P 856564-63-1P 856564-64-2P 856564-65-3P 856564-66-4P 856564-67-5P 856564-68-6P 856564-69-7P 856564-70-0P 856564-71-1P 856564-72-2P 856564-73-3P 856564-74-4P 856645-86-8P, 4-[[4-(Aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(1R)-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide


856645-89-1P 856645-92-6P 856645-96-0P,
4-[(4-Acetylcyclohexyl)amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE4B inhibitor; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)


RN 856561-41-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-42-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-43-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chloro-4-methylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-44-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dimethylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-45-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-46-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-47-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chloro-4-methylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-48-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(3-hydroxyphenyl)ethyl]- (CA INDEX NAME)



RN 856561-49-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino) cyclohexyl]amino]-N-[1-(3-hydroxyphenyl)propyl]- (CA INDEX NAME)



RN 856561-50-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino) cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-51-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino) cyclohexyl]amino]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 856561-52-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-[4-(1-methylethoxy)phenyl]ethyl]-, (+)- (CA INDEX NAME)

Rotation (+).



RN 856561-53-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-[4-(1-methylethoxy)phenyl]ethyl]- (CA INDEX NAME)



RN 856561-54-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[[4-(hydroxyimino)cyclohexyl]amino]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 856561-55-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-1-


ethyl-4-[(3-hydroxycyclohexyl)amino]- (CA INDEX NAME)



RN 856561-57-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[(3-hydroxycyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-58-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1S)-1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[(3-hydroxycyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856561-59-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[(3-hydroxycyclohexyl)amino]- (CA INDEX NAME)




RN 856561-60-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856561-61-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856561-68-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1S)-1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-76-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 856561-80-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1S)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 856561-81-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-82-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-83-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-84-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-

piperidinyl]amino]-N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856561-85-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[1-(3-chloro-4-methylphenyl)propyl]-1-ethyl- (CA INDEX NAME)



RN 856561-86-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl- (CA INDEX NAME)



RN 856561-87-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,5-dimethylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-88-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(1R)-1-(2,4,6-trimethylphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-89-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(2-ethylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-90-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-ethylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-91-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-ethylphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-92-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,6-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-93-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,5-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-94-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(2-ethylphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-95-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(1R)-1-(2,4,6-trimethylphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-96-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(2,5-dimethylphenyl)ethyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-97-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(4-ethylphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-98-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(2-ethylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(2,4,6-trimethylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-01-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[1-(4-chlorophenyl)ethyl]-1-ethyl- (CA INDEX NAME)




RN 856562-02-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-03-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[1-(4-chlorophenyl)propyl]-1-ethyl- (CA INDEX NAME)



RN 856562-04-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[1-(4-fluorophenyl)propyl]- (CA INDEX NAME)



RN 856562-05-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-06-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(4-ethylphenyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-07-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-[4-(1-methylethyl)phenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856562-08-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-09-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(2,6-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-10-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(2,5-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-11-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(2-ethylphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-12-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(2,4,6-trimethylphenyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-13-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[1-(4-chlorophenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856562-14-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[1-[4-(4-chlorophenyl)ethyl]-1-ethyl]- (CA INDEX NAME)




RN 856562-15-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[1-(4-chlorophenyl)ethyl]-1-ethyl- (CA INDEX NAME)



RN 856562-16-8 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[1-(4-fluorophenyl)propyl]-
(CA INDEX NAME)



RN 856562-17-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-
(CA INDEX NAME)


Absolute stereochemistry.



RN 856562-18-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-19-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-20-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-21-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[trans-4-(aminocarbonyl)cyclohexyl]amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-22-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[trans-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-23-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[trans-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-24-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[trans-4-(aminocarbonyl)cyclohexyl]amino]-N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-25-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-26-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(3S)-1-(aminocarbonyl)-3-

pyrrolidinyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-27-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-28-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-29-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-30-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-31-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-32-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-33-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-3-(aminocarbonyl)cyclobutyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 856562-34-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-3-(aminocarbonyl)cyclobutyl]amino]-N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-
(CA INDEX NAME)


Relative stereochemistry.



RN 856562-35-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(trans-4-acetylcyclohexyl)amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 856562-36-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(cis-4-acetylcyclohexyl)amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856562-37-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[[4-(1-hydroxyethyl)cyclohexyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-38-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl-4-[(3-hydroxycyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-39-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[[(1R, 3R)-3-hydroxycyclohexyl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 856562-40-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[4-(dimethylamino)-1-(3-methylphenyl)-4-oxobutyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856562-41-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[4-(dimethylamino)-1-(3-methylphenyl)-4-oxobutyl]-1-ethyl- (CA INDEX NAME)



RN 856562-42-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-4-(4-piperidinylamino)-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



•x HCl

RN 856562-43-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-(4-piperidinylamino)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 856564-62-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-[4-(1-methylethoxy)phenyl]ethyl]-, (-)- (CA INDEX NAME)


Rotation (-).



RN 856564-63-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[[4-(hydroxyimino)cyclohexyl]amino]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 856564-64-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-N-[1-(4-chlorophenyl)propyl]-1-ethyl-
 (CA INDEX NAME)

Relative stereochemistry.




RN 856564-65-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856564-66-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-N-[1-[4-(difluoromethoxy)phenyl]ethyl]-1-ethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 856564-67-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-N-[1-(4-chlorophenyl)ethyl]-1-ethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 856564-68-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[1-(4-fluorophenyl)propyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 856564-69-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-70-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(1R)-1-(3,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 856564-71-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-72-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(1R)-1-(3,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-73-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[(3-hydroxycyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-74-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-(4-piperidinylamino)-, monohydrochloride

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 856645-86-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(1S)-1-phenylethyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 856645-89-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856645-92-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856645-96-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(4-acetylcyclohexyl)amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 856564-82-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(intermediate; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)

RN 856564-82-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



IT 856563-57-0P, 1,1-Dimethylethyl 4-[[[1-ethyl-5-[[[(1R)-1-(4-methylphenyl)ethyl]amino]carbonyl]-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]-1-piperidinecarboxylate 856563-58-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)

RN 856563-57-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-ethyl-5-[[[(1R)-1-(4-methylphenyl)ethyl]amino]carbonyl]-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-58-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[5-[[[(1R)-1-(2,4-dimethylphenyl)propyl]amino]carbonyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 856564-26-6P


RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PUR (Purification or recovery); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)

RN 856564-26-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




IT 856564-14-2P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PUR (Purification or recovery); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)

RN 856564-14-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



IT 856564-18-6P 856564-19-7P 856564-20-0P
 856564-21-1P 856564-22-2P 856564-23-3P
 856564-24-4P 856564-25-5P 856564-27-7P
 856564-28-8P 856564-29-9P 856564-30-2P
 856564-31-3P 856564-32-4P 856564-33-5P
 856564-34-6P 856564-35-7P 856564-36-8P
 856564-37-9P 856564-38-0P 856564-39-1P
 856564-40-4P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)

RN 856564-18-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-[4-(difluoromethoxy)phenyl]ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-19-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-20-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(2-methylphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-21-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-ethoxyphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-22-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-[4-(difluoromethoxy)phenyl]propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-23-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[(1R)-1-[4-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-24-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-25-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,3-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-27-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chloro-2-fluorophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-28-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-methylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-29-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,3-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-30-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-31-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-32-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-methylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-33-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-hydroxyphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-34-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-methoxyphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-35-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methoxyphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-36-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-37-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[(1R)-1-(4-propoxyphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-38-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3,5-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-39-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methylphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-40-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-[4-(1-methylethyl)phenyl]propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



IT 856563-69-4P 856563-70-7P 856563-71-8P
 856563-72-9P 856563-73-0P 856563-74-1P
 856563-75-2P 856563-76-3P 856563-77-4P
 856563-78-5P 856563-79-6P 856563-80-9P
 856563-81-0P 856563-82-1P 856563-83-2P
 856563-84-3P 856563-85-4P 856563-86-5P
 856563-87-6P 856563-88-7P 856563-89-8P
 856563-90-1P 856563-91-2P 856563-92-3P
 856563-93-4P 856563-94-5P 856563-95-6P

856563-96-7P 856563-97-8P 856563-98-9P
 856563-99-0P 856564-00-6P 856564-01-7P
 856564-02-8P 856564-03-9P 856564-04-0P
 856564-05-1P 856564-06-2P 856564-07-3P
 856564-08-4P 856564-09-5P 856564-10-8P
 856564-11-9P 856564-12-0P 856564-13-1P
 856564-15-3P 856564-16-4P 856564-17-5P
 856564-41-5P 856564-42-6P 856564-43-7P
 856564-44-8P 856564-45-9P 856564-46-0P
 856564-47-1P 856564-48-2P 856564-49-3P
 856564-50-6P 856564-51-7P 856564-52-8P
 856564-53-9P 856564-54-0P 856564-55-1P
 856564-56-2P 856564-57-3P 856564-58-4P
 856564-59-5P 856564-60-8P 856564-61-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of
 inflammatory and/or allergic diseases)

RN 856563-69-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-
 [(1R)-1-(3-methoxyphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-70-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-
 [(1R)-1-(4-methoxyphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-71-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)propyl]-
 4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-72-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-propoxyphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-73-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(3,5-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-74-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-methylphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-75-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-[4-(1-methylethyl)phenyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-76-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(2-methylphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-77-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-[4-(difluoromethoxy)phenyl]ethyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-78-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-79-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(2-methylphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-80-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(4-ethoxyphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-81-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-[4-(difluoromethoxy)phenyl]propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-82-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-[4-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-83-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(3,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-84-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(2,3-dimethylphenyl)ethyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-85-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(2,4-dimethylphenyl)ethyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-86-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chloro-2-fluorophenyl)ethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-87-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-methylphenyl)ethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-88-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(2,3-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-89-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-90-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chloro-2-fluorophenyl)propyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-91-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-methylphenyl)propyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-92-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(3-hydroxyphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-93-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1S)-1-(4-chlorophenyl)-2-hydroxyethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-94-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(3-methoxyphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856563-95-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-methoxyphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856563-96-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-bromophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856563-97-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-propoxyphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856563-98-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856563-99-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-methylphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-00-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-[4-(1-methylethyl)phenyl]propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-01-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(2-methylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-02-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[4-(difluoromethoxy)phenyl]ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-03-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 856564-04-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(2-methylphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-05-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-ethoxyphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-06-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[4-(difluoromethoxy)phenyl]propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-07-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[1-[4-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)




RN 856564-08-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-09-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dimethylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-10-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-11-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-12-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chloro-4-methylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-13-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-15-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-16-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chloro-4-methylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856564-17-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(3-hydroxyphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856564-41-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-(3-methoxyphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-42-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-(4-methoxyphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-43-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-44-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-(4-propoxyphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-45-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3,5-dimethylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-46-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-(4-methylphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-47-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-[4-(1-methylethyl)phenyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-48-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-[4-(difluoromethoxy)phenyl]ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-49-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-50-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-(2-methylphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-51-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-ethoxyphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-52-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-[4-(difluoromethoxy)phenyl]propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-53-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-[4-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-54-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,3-dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-55-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chloro-2-fluorophenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-56-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-methylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-57-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,3-dimethylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-58-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-59-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-60-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-methylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-61-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-(3-hydroxyphenyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:160835 CAPLUS

DOCUMENT NUMBER: 142:254632

TITLE: Methods for treating neurodegenerative diseases by inhibiting phosphodiesterase 4 activity using compounds in pyrazolopyridine family

INVENTOR(S): Schweighoffer, Fabien; Guillet, Philippe

PATENT ASSIGNEE(S): Exonhit Therapeutics Sa, Fr.

SOURCE: U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U.S. Ser. No. 486,639.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043319	A1	20050224	US 2004-857455	20040601
FR 2828693	A1	20030221	FR 2001-10819	20010814
FR 2828693	B1	20040618		
US 2003064374	A1	20030403	US 2001-983754	20011025
US 6855736	B2	20050215		
WO 2003016563	A2	20030227	WO 2002-FR2861	20020813
WO 2003016563	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004219552	A1	20041104	US 2004-486639	20040212
PRIORITY APPLN. INFO.:			FR 2001-10819	A 20010814
			US 2001-983754	A2 20011025
			WO 2002-FR2861	W 20020813
			US 2004-486639	A2 20040212

AB The present invention relates to new methods for the detection, characterization and/or treatment (or management) of neurodegenerative diseases, particularly amyotrophic lateral sclerosis. In particular, the invention describes the role of PDE4B in these diseases and its use as a therapeutic, diagnostic or exptl. target. Specifically, the method for the treatment of respiratory disorders associated with ALS, comprises


administering to a subject in need of such treatment a compound that inhibits PDE4, preferably a compound that selectively inhibits PDE4. The compound is an antisense nucleic acid, capable of inhibiting transcription of the PDE4B gene or translation of the corresponding messenger. The compound is also chosen from among the compds. in the pyrazolopyridine family, particularly etazolate, and the compds. in the family of xanthine derivs., particularly pentoxifylline.

IT 103585-88-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for treating neurodegenerative diseases by inhibiting phosphodiesterase 4 activity using compds. in pyrazolopyridine family)

RN 103585-88-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-amino-1-pentyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:588 CAPLUS

DOCUMENT NUMBER: 142:86671

TITLE: Methods and compositions for the treatment of cognitive deficiencies with ligands for the benzodiazepine peripheral receptor

INVENTOR(S): Schweighoffer, Fabien; Desire, Laurent; Resink, Annelies

PATENT ASSIGNEE(S): Exonhit Therapeutics S. A., Fr.

SOURCE: Fr. Demande, 34 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2856595	A1	20041231	FR 2003-7824	20030627
AU 2004251466	A1	20050106	AU 2004-251466	20040625
CA 2528284	A1	20050106	CA 2004-2528284	20040625
WO 2005000302	A1	20050106	WO 2004-FR1630	20040625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1638559	A1	20060329	EP 2004-767477	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				


IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 CN 1812786 A 20060802 CN 2004-80018148 20040625
 JP 2007520427 T 20070726 JP 2006-516332 20040625
 IN 2005DN05464 A 20070817 IN 2005-DN5464 20051128
 US 2006142326 A1 20060629 US 2005-560774 20051214
 PRIORITY APPLN. INFO.: FR 2003-7824 A 20030627
 WO 2004-FR1630 W 20040625

AB The present invention relates to methods to improve, increase or facilitate the cognitive ability of subjects afflicted with neurodegenerative disorders. The invention more particularly involves ligands for the benzodiazepine peripheral receptor, preferably ligands of the pyrazolopyridine family, for the improvement of cognitive abilities in subjects afflicted with neurodegenerative disorders, particularly those with Alzheimer's disease.

IT 103585-88-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods and compns. for treatment of cognitive deficiencies with ligands for benzodiazepine peripheral receptor)

RN 103585-88-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-amino-1-pentyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:934227 CAPLUS

DOCUMENT NUMBER: 141:388737

TITLE: Phosphodiesterase 4B gene mutations in diagnosis of brain disorders and PDE4B inhibitors for treatment of brain disorders

INVENTOR(S): Ait, Ikhlef Ali; Resink, Annelies; Schweighoffer, Fabien

PATENT ASSIGNEE(S): Fr.

SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 983,754.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004219552	A1	20041104	US 2004-486639	20040212
FR 2828693	A1	20030221	FR 2001-10819	20010814
FR 2828693	B1	20040618		
US 2003064374	A1	20030403	US 2001-983754	20011025
US 6855736	B2	20050215		
WO 2003016563	A2	20030227	WO 2002-FR2861	20020813


WO 2003016563 A3 20040401
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2005043319 A1 20050224 US 2004-857455 20040601
PRIORITY APPLN. INFO.: FR 2001-10819 A 20010814
US 2001-983754 A2 20011025
WO 2002-FR2861 W 20020813
US 2004-486639 A2 20040212

AB The invention describes the role of phosphodiesterase 4B (PDE4B) in neurodegenerative diseases and its use as a therapeutic or diagnostic target. Thus, antisense nucleic acids, pyrazolopyridines, and xanthine derivs. may be used to inhibit PDE4B and treat these diseases. Primers and probes for detecting mutations in PDE4B nucleic acids may be used in diagnosis of such diseases. Thus, PDE4B was demonstrated to be involved in excitotoxicity, especially in an ALS model, and inhibitors of PDE4B (etazolate and pentoxifylline) were shown to preserve neuronal viability during stress linked to excitotoxicity.

IT 103585-88-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (phosphodiesterase 4B gene mutations in diagnosis of brain disorders and PDE4B inhibitors for treatment of brain disorders)

RN 103585-88-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-amino-1-pentyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:550957 CAPLUS
DOCUMENT NUMBER: 141:106464
TITLE: Preparation of pyrazolo[3,4-b]pyridine derivatives for use in pharmaceutical compositions as phosphodiesterase inhibitors
INVENTOR(S): Allen, David George; Coe, Diane Mary; Cook, Caroline Mary; Cooper, Anthony William James; Dowle, Michael Dennis; Edlin, Christopher David; Hamblin, Julie Nicole; Johnson, Martin Redpath; Jones, Paul Spencer; Lindvall, Mika Kristian; Mitchell, Charlotte Jane; Redgrave, Alison Judith
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 244 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056823	A1	20040708	WO 2003-EP14867	20031219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2511340	A1	20040708	CA 2003-2511340	20031219
AU 2003293999	A1	20040714	AU 2003-293999	20031219
EP 1581532	A1	20051005	EP 2003-789413	20031219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017645	A	20051206	BR 2003-17645	20031219
CN 1751042	A	20060322	CN 2003-80109835	20031219
JP 2006513258	T	20060420	JP 2005-502565	20031219
AU 2004299277	A1	20050630	AU 2004-299277	20041217
CA 2557004	A1	20050630	CA 2004-2557004	20041217
WO 2005058892	A1	20050630	WO 2004-EP14490	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1737857	A1	20070103	EP 2004-804089	20041217
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
CN 1914205	A	20070214	CN 2004-80041657	20041217
JP 2007514704	T	20070607	JP 2006-544380	20041217
IN 2005KN01207	A	20070713	IN 2005-KN1207	20050622
MX 2005PA06923	A	20050818	MX 2005-PA6923	20050623
NO 2005003600	A	20050822	NO 2005-3600	20050722
US 2006252790	A1	20061109	US 2006-540371	20060221
US 2007111995	A1	20070517	US 2006-596561	20060616
IN 2006KN01988	A	20070518	IN 2006-KN1988	20060714
NO 2006003340	A	20060912	NO 2006-3340	20060718
PRIORITY APPLN. INFO.:				
			GB 2002-30045	A 20021223
			GB 2002-30165	A 20021224
			GB 2003-7998	A 20030407
			WO 2003-EP14867	W 20031219
			WO 2003-EP314867	A 20031219
			GB 2004-5899	A 20040316
			GB 2004-5936	A 20040316
			GB 2004-6754	A 20040325
			WO 2004-EP14490	W 20041217

OTHER SOURCE(S): MARPAT 141:106464
GI



AB Pyrazolo[3,4-b]pyridine derivs., such as I [R = heterocyclyl; R1 = (CH₂)₂OH, alkyl, fluoroalkyl; R2 = H, Me, fluoroalkyl; R3 = alkyl, (un)substituted-Ph, cycloalkyl, heterocyclyl, etc.; R3a = H, alkyl], were prepared for therapeutic uses as inhibitors of phosphodiesterase, particularly phosphodiesterase IV (PDE4). These pyrazolo[3,4-b]pyridines were claimed for use in the treatment and/or prophylaxis of cognitive impairment and inflammatory and/or allergic diseases, such as chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis. Thus, pyrazolo[3,4-b]pyridine derivative II was prepared via a cyclocondensation reaction of hydrazide III using POCl₃ in MeCN. The prepared pyrazolo[3,4-b]pyridine were assayed for PDE4 inhibitory activity, and systems for delivery of these PDE4 inhibitors were discussed.

IT 720705-46-4P 720705-47-5P 720705-50-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolo[3,4-b]pyridine derivs. for use in pharmaceutical compns. as phosphodiesterase inhibitors)

RN 720705-46-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-2-hydroxy-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 720705-47-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-2-hydroxy-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 720705-50-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S,2R)-2-hydroxy-1-phenylpropyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:252512 CAPLUS

DOCUMENT NUMBER: 140:287376

TITLE: Preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase inhibitors for treatment of COPD, asthma, or allergic rhinitis

INVENTOR(S): Allen, David George; Coe, Diane Mary; Cook, Caroline Mary; Dowle, Michael Dennis; Edlin, Christopher David; Hamblin, Julie Nicole; Johnson, Martin Redpath; Jones, Paul Spencer; Knowles, Richard Graham; Lindvall, Mika Kristian; Mitchell, Charlotte Jane; Redgrave, Alison Judith; Trivedi, Naimisha; Ward, Peter

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024728	A2	20040325	WO 2003-EP11814	20030912
WO 2004024728	A3	20041021		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2497550	A1	20040325	CA 2003-2497550	20030912
AU 2003285300	A1	20040430	AU 2003-285300	20030912
EP 1539753	A2	20050615	EP 2003-778283	20030912

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK



BR 2003014392	A	20050712	BR 2003-14392	20030912
CN 1694882	A	20051109	CN 2003-825043	20030912
JP 2006503108	T	20060126	JP 2004-571743	20030912
NZ 538515	A	20070427	NZ 2003-538515	20030912
NO 2005000841	A	20050615	NO 2005-841	20050216
MX 2005PA02887	A	20050527	MX 2005-PA2887	20050315
IN 2005KN00473	A	20060609	IN 2005-KN473	20050321
US 2006089375	A1	20060427	US 2005-527866	20050927

PRIORITY APPLN. INFO.:

GB 2002-21455	A	20020916
GB 2002-30045	A	20021223
GB 2003-6595	A	20030321
GB 2003-8017	A	20030407
GB 2003-19708	A	20030821
GB 2003-21074	A	20030909
WO 2003-EP11814	W	20030912
WO 2003-GB11814	W	20030912

OTHER SOURCE(S): MARPAT 140:287376


GI



AB Title compds. I [wherein R1 = (fluoro)alkyl, (CH₂)₂OH, (CH₂)₂CO₂-alkyl; R2 = HMe, fluoroalkyl; R3 = (un)substituted cycloalkyl, cycloalkenyl, or heterocyclyl; X = NR₄R₅, OR_{5a}; R4 = H, (fluoro)alkyl, (un)substituted cycloalkyl(alkyl); R5 = substituted alkyl, acyl(alkyl), carboxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), alkylsulfonyl(alkyl), or cyano(alkyl); R_{5a} = (fluoro)alkyl, cycloalkyl(alkyl), substituted Ph; and salts thereof] were prepared as phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. The invention also provides for the use of I or pharmaceutically acceptable salts thereof for the treatment and/or prophylaxis of an inflammatory and/or allergic disease, such as chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis. For example, 4-chloro-1-ethyl-N-(4-fluorophenyl)1H-pyrazolo[3,4-b]pyridine-5-carboxamide (preparation given) was coupled with 4-aminotetrahydropyran in EtOH using TEA to give II. The latter inhibited human recombinant PDE 4B with a pIC₅₀ of 7.9 and suppressed LPS-induced pulmonary neutrophilia in rats with an ED₅₀ in the range of about 0.5 mg/kg to about 2 mg/kg. In the rat pica model of emesis, II exhibited pica response values (ED₅₀ ranging from


4.8 mg/kg to 40 mg/kg) higher than the neutrophilia-inhibition doses and displayed a therapeutic index >2. Thus, II showed anti-inflammatory effects with low emetic side effects.

- IT 675115-13-6P, N-[(2,4-Dimethylphenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-14-7P, N-[(3,4-Dimethylphenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-16-9P, 1-Ethyl-N-[[4-(methyloxy)phenyl]methyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-18-1P, N-[[4-(Dimethylamino)phenyl]methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-19-2P, N-[[4-[(Difluoromethyl)oxy]phenyl]methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-20-5P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[[4-(trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-05-9P, Methyl 3-[[1-ethyl-5-[(phenylmethyl)amino]carbonyl]-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]cyclohexanecarboxylate
 675116-08-2P, N-Benzyl-1-ethyl-4-[[1-[(methyloxy)acetyl]-4-piperidinyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-20-1P, Methyl 3-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]benzoate
 675117-22-3P, Methyl 4-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]benzoate
 675117-72-3P, N-[(3,4-Dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675118-52-2P, Methyl 3-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]benzoate
 675118-90-8P, Methyl 4-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]benzoate
 675119-56-9P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[[4-(methyloxy)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-81-0P, N-[(3-Chloro-4-methylphenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-82-1P, N-[(4-Chloro-2-methylphenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (PDE4 inhibitor; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic disease)
 RN 675115-13-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-dimethylphenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




- RN 675115-14-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethylphenyl)methyl]-1-

ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675115-16-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-methoxyphenyl)methyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675115-18-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(dimethylamino)phenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675115-19-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(difluoromethoxy)phenyl]methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675115-20-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 675116-05-9 CAPLUS


CN Cyclohexanecarboxylic acid, 3-[[1-ethyl-5-[[[(phenylmethyl)amino]carbonyl]-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]-, methyl ester (CA INDEX NAME)




RN 675116-08-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[1-(methoxyacetyl)-4-piperidinyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 675117-20-1 CAPLUS
 CN Benzoic acid, 3-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 675117-22-3 CAPLUS
 CN Benzoic acid, 4-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 675117-72-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-52-2 CAPLUS
CN Benzoic acid, 3-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 675118-90-8 CAPLUS
CN Benzoic acid, 4-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 675119-56-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 675119-81-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 675119-82-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-chloro-2-methylphenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



IT 675112-98-8P, N-Benzyl-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-17-4P, N-Benzyl-4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-19-6P, N-Benzyl-4-(cyclohexylamino)-1-ethyl-

1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-21-0P,
4-[(1-Acetylpiperidin-4-yl)amino]-N-benzyl-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-39-0P, N-Benzyl-4-(cyclopentylamino)-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-40-3P, N-Benzyl-4-(cyclohexylamino)-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-41-4P, N-Benzyl-1-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-50-5P, 4-[(1-Acetylpiperidin-4-yl)amino]-N-benzyl-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-59-4P, (S)-N-Benzyl-1-ethyl-4-[(tetrahydrofuran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-60-7P, (R)-N-Benzyl-1-ethyl-4-[(tetrahydrofuran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-61-8P, N-Benzyl-1-ethyl-4-[(tetrahydrothien-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-62-9P, N-Benzyl-4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-63-0P, N-Benzyl-4-[(1,1-dioxidotetrahydrothien-3-yl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-64-1P, N-Benzyl-4-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-65-2P, N-Benzyl-1-ethyl-4-[(tetrahydro-2H-thiopyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-73-2P, 1-Ethyl-N-[4-(methylsulfonyl)benzyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-74-3P, 1-Ethyl-N-[3-(methylsulfonyl)benzyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-84-5P, N-[3-(tert-Butoxymethyl)benzyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-88-9P, N-(2-Chloro-6-fluorobenzyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-90-3P, N-[3-(Aminocarbonyl)benzyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-99-2P, N-[2-(Dimethylamino)benzyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-03-1P, N-[4-[(Dimethylamino)sulfonyl]benzyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-04-2P, 1-Ethyl-N-[3-[(methylsulfonyl)amino]benzyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-17-7P, 1-Ethyl-N-(4-methoxybenzyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-23-5P, N-(2,5-Difluorobenzyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-24-6P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[4-(trifluoromethyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-29-1P, N-(3,4-Difluorobenzyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-36-0P, N-(3,4-Dimethoxybenzyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-37-1P, N-(3-Chlorobenzyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-53-1P, N-[4-(Methylsulfonyl)benzyl]-1-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-57-5P, 4-(Cyclohexylamino)-1-ethyl-6-methyl-N-[4-(methylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-58-6P, N-Benzyl-4-(cyclohexylamino)-1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-60-0P, 4-(Cyclohexylamino)-1-ethyl-6-methyl-N-[4-(trifluoromethyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-62-2P, N-Benzyl-1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-69-9P, 4-[(cis-4-Aminocyclohexyl)amino]-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-70-2P, 4-(Cyclobutylamino)-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-71-3P, 4-(Cycloheptylamino)-1-ethyl-N-(phenylmethyl)-1H-

pyrazolo[3,4-b]pyridine-5-carboxamide 675114-72-4P,
1-Ethyl-4-[(4-methylcyclohexyl)amino]-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-73-5P, N-Benzyl-1-ethyl-4-[(2-oxoazepan-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-74-6P, N-Benzyl-1-ethyl-4-[(3-hydroxycyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-75-7P, N-Benzyl-1-ethyl-4-[(4-hydroxycyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-76-8P, N-Benzyl-1-ethyl-4-[(3-hydroxycyclopentyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-77-9P, N-Benzyl-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-80-4P, 1-Ethyl-4-[(3-methylcyclohexyl)amino]-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-81-5P, 1-Ethyl-4-[(1-methylcyclohexyl)amino]-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-82-6P, 4-[(1R,2R,4S)-Bicyclo[2.2.1]hept-2-yl)amino]-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-83-7P, 4-[(1R,2S,4S)-Bicyclo[2.2.1]hept-2-yl)amino]-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-84-8P, (S)-1-Ethyl-4-[(2-oxo-3-pyrrolidinyl)amino]-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-85-9P, 4-[(2,5-Dioxo-3-pyrrolidinyl)amino]-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-86-0P, 4-(1-Azabicyclo[2.2.2]oct-3-ylamino)-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-87-1P, 1-Ethyl-4-[(1-methylcyclohexyl)amino]-N-[[4-(methyloxy)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-88-2P, 4-(Cyclobutylamino)-1-ethyl-N-[[4-(methyloxy)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-89-3P, 4-(Cycloheptylamino)-1-ethyl-N-[[4-(methyloxy)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-90-6P, 4-[(1R,2R,4S)-Bicyclo[2.2.1]hept-2-yl)amino]-1-ethyl-N-[[4-(methyloxy)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-91-7P, 1-Ethyl-4-[(4-methylcyclohexyl)amino]-N-[[4-(methyloxy)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-92-8P, 1-Ethyl-4-[(3-methylcyclohexyl)amino]-N-[[4-(methyloxy)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-93-9P, 4-[(1R,2S,4S)-Bicyclo[2.2.1]hept-2-yl)amino]-1-ethyl-N-[[4-(methyloxy)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-94-0P, 4-[(cis-4-Aminocyclohexyl)amino]-1-ethyl-N-[[4-(methyloxy)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-95-1P, 4-(Cycloheptylamino)-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-96-2P, 4-(Cyclobutylamino)-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-97-3P, 4-[(1R,2R,4S)-Bicyclo[2.2.1]hept-2-yl)amino]-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-98-4P, 4-[(1R,2S,4S)-Bicyclo[2.2.1]hept-2-yl)amino]-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-99-5P, 1-Ethyl-4-[(4-methylcyclohexyl)amino]-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-00-1P, 1-Ethyl-4-[(3-methylcyclohexyl)amino]-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-01-2P, 1-Ethyl-4-[(1-methylcyclohexyl)amino]-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-02-3P, 4-[(cis-4-Aminocyclohexyl)amino]-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-03-4P, 4-(Cyclohexylamino)-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-15-8P, N-[(3,4-Dichlorophenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-17-0P, 1-Ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]-4-[(4-oxocyclohexyl)amino]-1H-

pyrazolo[3,4-b]pyridine-5-carboxamide 675115-21-6P,
 1-Ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]-4-[(4-oxocyclohexyl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675115-30-7P,
 1-Ethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-3-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675115-31-8P,
 N-[[4-[(difluoromethyl)oxy]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-
 3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-32-9P
 , 1-Ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]-N-[[4-
 (trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-33-0P, 1-Ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]-4-
 [(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-43-2P, 4-[(4,4-Difluorocyclohexyl)amino]-1-ethyl-N-
 (phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-44-3P, 1-Ethyl-4-[(4-fluoro-3-cyclohexen-1-yl)amino]-N-
 (phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-46-5P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(3,4-
 dichlorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-47-6P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(3-
 fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-48-7P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(3,4-
 difluorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-49-8P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(2,5-
 difluorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-50-1P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[[3-
 (trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-51-2P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[[4-
 (trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-52-3P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(2,6-
 difluorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-53-4P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(3-
 chlorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-54-5P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[[4-
 (methyloxy)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-56-7P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[[4-
 [(dimethylamino)sulfonyl]phenyl]methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-
 5-carboxamide 675115-58-9P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-
 [[2-(dimethylamino)phenyl]methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675115-59-0P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-
 [(2,4-dichlorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675115-60-3P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-
 ethyl-N-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-61-4P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(2-chloro-6-
 fluorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675115-62-5P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[[4-
 [(difluoromethyl)oxy]phenyl]methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675115-63-6P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-
 [[3-chloro-4-(methyloxy)phenyl]methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-
 5-carboxamide 675115-67-0P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-
 ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675115-69-2P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-
 ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]-1H-pyrazolo[3,4-
 b]pyridine-5-carboxamide 675115-70-5P, 4-[(1-Acetyl-4-
 piperidinyl)amino]-1-ethyl-N-[[4-[(methylamino)carbonyl]phenyl]methyl]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675115-71-6P,
 4-[(1-Acetyl-4-piperidinyl)amino]-N-[[4-(aminosulfonyl)phenyl]methyl]-1-
 ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-72-7P,
 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[[3-
 [(methylamino)carbonyl]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675115-73-8P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-
 [[4-(aminocarbonyl)phenyl]methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675116-06-0P, 3-[[1-Ethyl-5-
 [(phenylmethyl)amino]carbonyl]-1H-pyrazolo[3,4-b]pyridin-4-
 yl]amino]cyclohexanecarboxylic acid 675116-07-1P,

1-Ethyl-N-(phenylmethyl)-4-(4-piperidinylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-12-8P, 1-Ethyl-6-methyl-N-[[4-(methylsulfonyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-70-8P, 4-(Cyclohexylamino)-1-ethyl-N-[[3-(methylsulfonyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-71-9P, N-[[3-(Aminocarbonyl)phenyl]methyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-73-1P, 4-(Cyclohexylamino)-N-[[4-[(dimethylamino)sulfonyl]phenyl]methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-75-3P, 4-(Cyclohexylamino)-1-ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-78-6P, 4-(Cyclohexylamino)-1-ethyl-N-[[3-[(methylamino)carbonyl]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-79-7P, N-[[4-(Aminocarbonyl)phenyl]methyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-80-0P, 4-(Cyclohexylamino)-1-ethyl-N-[(4-hydroxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-81-1P, 4-(Cyclohexylamino)-1-ethyl-N-[[4-(methyloxy)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-82-2P, 4-(Cyclohexylamino)-N-[(3,4-difluorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-83-3P, 4-(Cyclohexylamino)-1-ethyl-N-[[4-(trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-84-4P, 4-(Cyclohexylamino)-1-ethyl-N-[[3-[(methylsulfonyl)amino]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-85-5P, 4-(Cyclohexylamino)-N-[(2,5-difluorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-86-6P, 4-(Cyclohexylamino)-1-ethyl-N-[(4-methylphenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-88-8P, 4-(Cyclohexylamino)-1-ethyl-N-[(2-hydroxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-89-9P, 4-(Cyclohexylamino)-N-[(3,4-dichlorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-90-2P, 4-(Cyclohexylamino)-N-[(3,5-dichlorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-93-5P, 4-(Cyclohexylamino)-1-ethyl-N-[[2-(methylsulfinyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-96-8P, 4-(Cyclohexylamino)-1-ethyl-N-[[2-[(methylamino)carbonyl]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-97-9P, 4-(Cyclohexylamino)-1-ethyl-N-[[2-(methylsulfonyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-98-0P, Methyl 2-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]benzoate 675117-01-8P, 4-(Cyclohexylamino)-1-ethyl-N-[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-02-9P, 4-(Cyclohexylamino)-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-08-5P, 4-(Cyclohexylamino)-N-[(3,5-difluorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-11-0P, 4-(Cyclohexylamino)-N-[[4-(dimethylamino)phenyl]methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide trifluoroacetate 675117-12-1P, 4-(Cyclohexylamino)-1-ethyl-N-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-13-2P, N-[[2,4-Bis(methyloxy)phenyl]methyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-17-6P, N-[[2-[Acetyl(methyl)amino]phenyl]methyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide trifluoroacetate 675117-18-7P, 4-(Cyclohexylamino)-1-ethyl-N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-19-8P, 4-(Cyclohexylamino)-N-[(2,6-dichlorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-24-5P, 4-(Cyclohexylamino)-N-[[4-[(difluoromethyl)oxy]phenyl]methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-26-7P, N-[(2-Chloro-6-fluorophenyl)methyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

675117-27-8P, N-[[2-(Aminocarbonyl)phenyl]methyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-28-9P, 4-(Cyclohexylamino)-N-[[2-(dimethylamino)phenyl]methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-29-0P, 4-(Cyclohexylamino)-1-ethyl-N-[[4-(fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-30-3P, 4-(Cyclohexylamino)-1-ethyl-N-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-31-4P, 4-(Cyclohexylamino)-N-[[2,6-difluorophenyl]methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-32-5P, 4-(Cyclohexylamino)-1-ethyl-N-[[3-(fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-33-6P, 4-(Cyclohexylamino)-1-ethyl-N-[[2-(trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-35-8P, 4-(Cyclohexylamino)-1-ethyl-N-[[4-[(methylamino)carbonyl]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-39-2P, 4-[[[4-(Cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]benzoic acid
 675117-40-5P, 3-[[[4-(Cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]benzoic acid 675117-45-0P, N-[[3-(4-Chloro-4-methylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-46-1P, N-[[4-(4-Chloro-2-methylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-47-2P, N-[[2-[(Di fluoromethyl)oxy]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-48-3P, 1-Ethyl-N-[[2-[(1-methylethyl)oxy]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-49-4P, 1-Ethyl-N-[[3-[(1-methylethyl)oxy]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-50-7P, N-[[3-[(Di fluoromethyl)oxy]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-51-8P, 1-Ethyl-N-[[4-(hydroxy-3-(methyloxy)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-52-9P
 , N-[[5-(Acetyl-2-hydroxyphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-54-1P, N-[[4-(Acetyl amino)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-78-9P, 1-Ethyl-N-[[2-(methylsulfinyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-82-5P, N-[[4-(Dimethylamino)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-88-1P, N-[[3-(Aminosulfonyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-90-5P, 1-Ethyl-N-[[4-(methylphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-92-7P, 1-Ethyl-N-[[4-(fluoro-3-(trifluoromethyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-94-9P, Methyl 2-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]benzoate
 675118-01-1P, N-[[2-[Acetyl(methyl)amino]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675118-31-7P, 1-Ethyl-N-[[4-(4-morpholinylmethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 trifluoroacetate 675118-35-1P, 1-Ethyl-N-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide trifluoroacetate
 675118-41-9P, 1-Ethyl-N-[[4-(1-methylethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675118-43-1P, N-[[3-(Cyclopentyloxy)-4-(methyloxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-46-4P, 1-Ethyl-N-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-

pyrazolo[3,4-b]pyridine-5-carboxamide trifluoroacetate
 675118-48-6P, N-[(2,4-Dichlorophenyl)methyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675118-49-7P, N-[(2,4-Difluorophenyl)methyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675118-50-0P, N-[(2-Chloro-4-fluorophenyl)methyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675118-54-4P, 1-Ethyl-N-[[3-(1-pyrrolidinylmethyl)phenyl]methyl]-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 trifluoroacetate 675118-56-6P, N-[[2,5-
 Bis(methyloxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-
 1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-57-7P,
 N-[[2,6-Bis(methyloxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-58-8P,
 1-Ethyl-N-[(2-fluorophenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675118-59-9P,
 N-[(3,5-Difluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-
 1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-60-2P,
 N-[(4-Chlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675118-63-5P,
 1-Ethyl-N-[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]-4-[(tetrahydro-2H-
 pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675118-64-6P, N-[[4-[(Cyclopropylamino)carbonyl]phenyl]methyl]-1-
 ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675118-65-7P, 1-Ethyl-N-[[4-(4-methyl-1-
 piperazinyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675118-66-8P,
 1-Ethyl-N-[[4-(1-pyrrolidinylmethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-
 4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-68-0P
 , N-[(2,5-Dichlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-69-1P,
 N-[(3,5-Diethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-
 1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-70-4P,
 N-[(2,3-Difluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-
 1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-71-5P,
 1-Ethyl-N-[[2-(methylsulfonyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-72-6P,
 1-Ethyl-N-[(3-hydroxyphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675118-73-7P,
 N-[[3,5-Bis(methyloxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-75-9P,
 N-[(3,5-Dichlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-
 1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-76-0P,
 N-[[2,4-Bis(methyloxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-77-1P,
 1-Ethyl-N-[[2-(methyloxy)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-78-2P,
 N-[(2,4-Dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-
 1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-79-3P,
 1-Ethyl-N-[[2-[(methylamino)carbonyl]phenyl]methyl]-4-[(tetrahydro-2H-
 pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675118-82-8P, N-[(2-Chlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-
 pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675118-84-0P, 1-Ethyl-N-[(2-hydroxyphenyl)methyl]-4-[(tetrahydro-
 2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675118-92-0P, N-[(3,4-Dichlorophenyl)methyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675118-94-2P, N-[[4-(Aminocarbonyl)phenyl]methyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675118-96-4P, N-[(2,6-Difluorophenyl)methyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675118-97-5P, 1-Ethyl-N-[(4-hydroxyphenyl)methyl]-4-[(tetrahydro-
 2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide


675119-00-3P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-04-7P, 1-Ethyl-N-[[4-[(methylamino)carbonyl]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-07-0P, 1-Ethyl-N-[(3-fluorophenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-09-2P, 1-Ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-11-6P, N-[[4-(Aminosulfonyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-12-7P, N-[[2-(Aminocarbonyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE4 inhibitor; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic disease)


RN 675112-98-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-17-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopentylamino)-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675113-19-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675113-21-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675113-39-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopentylamino)-1-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675113-40-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675113-41-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-methyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675113-50-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-1-methyl-N-(phenylmethyl)- (CA INDEX NAME)



RN 675113-59-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[[(3S)-tetrahydro-3-furanyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 675113-60-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[[(3R)-tetrahydro-3-furanyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 675113-61-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-3-thienyl)amino]- (CA INDEX NAME)




RN 675113-62-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopropylamino)-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675113-63-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-1,1-dioxido-3-thienyl)amino]- (CA INDEX NAME)




RN 675113-64-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-65-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-thiopyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-73-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675113-74-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[3-(methylsulfonyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-84-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-[(1,1-dimethylethoxy)methyl]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-88-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-chloro-6-fluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-90-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-(aminocarbonyl)phenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-99-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[2-(dimethylamino)phenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-03-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-[(dimethylamino)sulfonyl]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-04-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[3-[(methylsulfonyl)amino]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-17-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-methoxyphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-23-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,5-difluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-24-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 675114-29-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-difluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-36-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethoxyphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-37-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3-chlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-53-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(methylsulfonyl)phenyl)methyl]-1-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-57-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-6-methyl-N-[[4-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 675114-58-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-6-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-60-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-6-methyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 675114-62-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-6-methyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675114-69-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(cis-4-aminocyclohexyl)amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 675114-70-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclobutylamino)-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-71-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cycloheptylamino)-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-72-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-methylcyclohexyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-73-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(hexahydro-2-oxo-1H-azepin-3-yl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-74-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(3-hydroxycyclohexyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-75-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-hydroxycyclohexyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-76-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(3-hydroxycyclopentyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-77-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-80-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(3-methylcyclohexyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)



RN 675114-81-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(1-methylcyclohexyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)



RN 675114-82-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN. 675114-83-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1R,2S,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 675114-84-8 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(3S)-2-oxo-3-pyrrolidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 675114-85-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(2,5-dioxo-3-pyrrolidinyl)amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-86-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(1-azabicyclo[2.2.2]oct-3-ylamino)-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-87-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-methoxyphenyl)methyl]-4-[(1-methylcyclohexyl)amino]- (CA INDEX NAME)




RN 675114-88-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclobutylamino)-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 675114-89-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cycloheptylamino)-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 675114-90-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 675114-91-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-methoxyphenyl)methyl]-4-[(4-methylcyclohexyl)amino]- (CA INDEX NAME)




RN 675114-92-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-methoxyphenyl)methyl]-4-[(3-methylcyclohexyl)amino]- (CA INDEX NAME)



RN 675114-93-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1R,2S,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 675114-94-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(cis-4-aminocyclohexyl)amino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 675114-95-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cycloheptylamino)-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)



RN 675114-96-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclobutylamino)-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)



RN 675114-97-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 675114-98-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1R,2S,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 675114-99-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-methylcyclohexyl)amino]-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)




RN 675115-00-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(3-methylcyclohexyl)amino]-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)



RN 675115-01-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(1-methylcyclohexyl)amino]-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)



RN 675115-02-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(cis-4-aminocyclohexyl)amino]-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 675115-03-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)




RN 675115-15-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dichlorophenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675115-17-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675115-21-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 675115-30-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-3-yl)amino]- (CA INDEX NAME)




RN 675115-31-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(difluoromethoxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]- (CA INDEX NAME)




RN 675115-32-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 675115-33-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-3-yl)amino]- (CA INDEX NAME)




RN 675115-43-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(4,4-difluorocyclohexyl)amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675115-44-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-fluoro-3-cyclohexen-1-yl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 675115-46-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(3,4-dichlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-47-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-N-[(3-fluorophenyl)methyl]- (CA INDEX NAME)




RN 675115-48-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidiny)amino]-N-[(3,4-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-49-8 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidiny)amino]-N-[(2,5-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-50-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 675115-51-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 675115-52-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(2,6-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-53-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-(3-chlorophenyl)methyl)-1-ethylpiperidinyl]amino]-N-[(3-chlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-54-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-(4-methoxyphenyl)methyl)-1-ethylpiperidinyl]amino]-N-[(4-methoxyphenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-56-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-[(4-(dimethylamino)sulfonyl]phenyl)methyl]piperidinyl)amino]-N-[(4-(dimethylamino)sulfonyl]phenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-58-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidiny] amino]-N-[[2-(dimethylamino)phenyl]methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-59-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidiny] amino]-N-[(2,4-dichlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-60-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidiny) amino]-1-ethyl-N-[(2-fluorophenyl)methyl]- (CA INDEX NAME)




RN 675115-61-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidiny) amino]-N-[(2-chloro-6-fluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-62-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidiny) amino]-N-[[4-(difluoromethoxy)phenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-63-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(3-chloro-4-methoxyphenyl)methyl]-1-ethyl- (CA INDEX NAME)



RN 675115-67-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-N-[[4-(methylsulfonyl)phenyl)methyl]- (CA INDEX NAME)




RN 675115-69-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl)methyl]- (CA INDEX NAME)




RN 675115-70-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)



RN 675115-71-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[[4-(aminosulfonyl)phenyl]methyl]-1-ethyl- (CA INDEX NAME)



RN 675115-72-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-

piperidiny] amino]-1-ethyl-N-[[3-[(methylamino) carbonyl]phenyl]methyl]-
(CA INDEX NAME)




RN 675115-73-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidiny] amino]-N-[[4-(aminocarbonyl)phenyl]methyl]-1-ethyl- (CA INDEX NAME)



RN 675116-06-0 CAPLUS


CN Cyclohexanecarboxylic acid, 3-[[1-ethyl-5-[[[(phenylmethyl) amino] carbonyl]-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]- (CA INDEX NAME)



RN 675116-07-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-(4-

piperidinylamino)- (CA INDEX NAME)




RN 675116-12-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-6-methyl-N-[[4-(methylsulfonyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-70-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[3-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 675116-71-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-(aminocarbonyl)phenyl]methyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 675116-73-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[[4-[(dimethylamino)sulfonyl]phenyl]methyl]-1-ethyl- (CA INDEX NAME)




RN 675116-75-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 675116-78-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[3-[(methylamino)carbonyl]phenyl]methyl]- (CA INDEX NAME)




RN 675116-79-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(aminocarbonyl)phenyl]methyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 675116-80-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(4-hydroxyphenyl)methyl]- (CA INDEX NAME)




RN 675116-81-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 675116-82-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(3,4-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675116-83-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 675116-84-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[3-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)




RN 675116-85-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(2,5-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675116-86-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(4-methylphenyl)methyl]- (CA INDEX NAME)




RN 675116-88-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(2-hydroxyphenyl)methyl]- (CA INDEX NAME)




RN 675116-89-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(3,4-dichlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675116-90-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(3,5-dichlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675116-93-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[2-(methylsulfinyl)phenyl]methyl]- (CA INDEX NAME)




RN 675116-96-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[2-[(methylsulfonyl)amino]methyl]phenyl]methyl- (CA INDEX NAME)




RN 675116-97-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[2-(methylsulfonyl)amino]methyl]phenyl]methyl- (CA INDEX NAME)




RN 675116-98-0 CAPLUS

CN Benzoic acid, 2-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 675117-01-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 675117-02-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(3,4-dimethylphenyl)methyl]-1-ethyl- (CA INDEX NAME)



RN 675117-08-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(3,5-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675117-11-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[[4-(dimethylamino)phenyl]methyl]-1-ethyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 675117-10-9


CMF C24 H32 N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 675117-12-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[2-fluorophenyl]methyl]- (CA INDEX NAME)



RN 675117-13-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(2,4-dimethoxyphenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675117-17-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[2-(acetylmethylamino)phenyl]methyl]-4-(cyclohexylamino)-1-ethyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 675117-16-5


CMF C25 H32 N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 675117-18-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-
[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 675117-19-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(2,6-
dichlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675117-24-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[[4-
(difluoromethoxy)phenyl]methyl]-1-ethyl- (CA INDEX NAME)




RN 675117-26-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-chloro-6-fluorophenyl)methyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)



RN 675117-27-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[2-(aminocarbonyl)phenyl]methyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 675117-28-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[[2-(dimethylamino)phenyl]methyl]-1-ethyl- (CA INDEX NAME)




RN 675117-29-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(4-fluorophenyl)methyl]- (CA INDEX NAME)




RN 675117-30-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 675117-31-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(2,6-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675117-32-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(3-fluorophenyl)methyl]- (CA INDEX NAME)




RN 675117-33-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 675117-35-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[4-[(methylamino)carbonyl]phenyl]methyl]- (CA INDEX NAME)




RN 675117-39-2 CAPLUS

CN Benzoic acid, 4-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 675117-40-5 CAPLUS

CN Benzoic acid, 3-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 675117-45-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-46-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-chloro-2-methylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675117-47-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[2-(difluoromethoxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-48-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[2-(1-methylethoxy)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-49-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[3-(1-methylethoxy)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-50-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-(difluoromethoxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-51-8 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-hydroxy-3-methoxyphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-52-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(5-acetyl-2-hydroxyphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675117-54-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(acetylamino)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-78-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[2-(methylsulfinyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-82-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(dimethylamino)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-(CA INDEX NAME)




RN 675117-88-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-(aminosulfonyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-(CA INDEX NAME)




RN 675117-90-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-methylphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-(CA INDEX NAME)




RN 675117-92-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-94-9 CAPLUS

CN Benzoic acid, 2-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)



RN 675118-01-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[2-(acetylmethylamino)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-31-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-(4-morpholinylmethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 675118-30-6


CMF C26 H34 N6 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 675118-35-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 675118-34-0


CMF C27 H37 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 675118-41-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-(1-methylethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675118-43-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-(cyclopentyloxy)-4-methoxyphenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-46-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 675118-45-3


CMF C27 H37 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 675118-48-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-dichlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-49-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-difluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675118-50-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-chloro-4-fluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-54-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[3-(1-pyrrolidinylmethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 675118-53-3


CMF C26 H34 N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 675118-56-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,5-dimethoxyphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-57-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,6-dimethoxyphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-58-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2-fluorophenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-59-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,5-difluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-60-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-63-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-64-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-[(cyclopropylamino)carbonyl]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-65-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-(4-methyl-1-piperazinyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-66-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-(1-pyrrolidinylmethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-(CA INDEX NAME)




RN 675118-68-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,5-dichlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-(CA INDEX NAME)




RN 675118-69-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,5-diethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-(CA INDEX NAME)




RN 675118-70-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,3-difluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-71-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[2-(methylsulfonyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-72-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(3-hydroxyphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-73-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,5-dimethoxyphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-75-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,5-dichlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-76-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-dimethoxyphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-77-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2-methoxyphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675118-78-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-79-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[2-[(methylamino)carbonyl]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-82-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-chlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-84-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2-hydroxyphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-92-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dichlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-94-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(aminocarbonyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-
(CA INDEX NAME)




RN 675118-96-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,6-difluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-97-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-hydroxyphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-00-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 675119-04-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-[(methylamino)carbonyl]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-07-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(3-fluorophenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-09-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-
(CA INDEX NAME)




RN 675119-11-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(aminosulfonyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-
(CA INDEX NAME)



RN 675119-12-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[2-(aminocarbonyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-
(CA INDEX NAME)



IT 675119-13-8P, N-[[4-[(Difluoromethyl)oxy]phenyl]methyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-14-9P, N-[[3-[(Dimethylamino)methyl]phenyl]methyl]-1-ethyl-
 4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675119-15-0P, N-[[3-Chloro-4-
 (methyloxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675119-17-2P,
 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[[2-(
 (trifluoromethyl)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-19-4P, N-[[3-[(Acetylamino)methyl]phenyl]methyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-20-7P, 1-Ethyl-N-[(4-fluorophenyl)methyl]-4-[(tetrahydro-2H-
 pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-21-8P, 1-Ethyl-N-[[4-fluoro-2-(trifluoromethyl)phenyl]methy
 l]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675119-22-9P, 1-Ethyl-N-[(2-ethylphenyl)methyl]-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-23-0P, 1-Ethyl-N-[[2-fluoro-5-(trifluoromethyl)phenyl]methy
 l]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675119-24-1P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-N-[(2,3,4-trifluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675119-25-2P, N-[(4-Chloro-2-fluorophenyl)methyl]-1-
 ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675119-26-3P, N-[(4-Bromo-2-fluorophenyl)methyl]-1-
 ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675119-27-4P, N-[(3,5-Dimethylphenyl)methyl]-1-ethyl-
 4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675119-28-5P, N-[(2,3-Dimethylphenyl)methyl]-1-ethyl-
 4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675119-29-6P, N-[(2,3-Dichlorophenyl)methyl]-1-ethyl-
 4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675119-30-9P, N-[(4-Cyanophenyl)methyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-31-0P, N-[(4-Bromophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-
 pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-32-1P, 1-Ethyl-N-[[5-fluoro-2-(trifluoromethyl)phenyl]methy
 l]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675119-33-2P, 1-Ethyl-N-[(4-iodophenyl)methyl]-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-34-3P, N-[[4-[(1,1-Dimethylethyl)phenyl]methyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-35-4P, N-[(3-Cyanophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-
 pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-36-5P, N-[(2,6-Dichlorophenyl)methyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-37-6P, N-[(5-Chloro-2-methylphenyl)methyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-38-7P, N-[(3,5-Dibromophenyl)methyl]-1-ethyl-4-[(tetrahydro-


2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-39-8P, 1-Ethyl-N-[(4-ethylphenyl)methyl]-4-[(tetrahydro-2H-
 pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-40-1P, 1-Ethyl-N-[[3-fluoro-4-(trifluoromethyl)phenyl]methy
 l]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675119-41-2P, 1-Ethyl-N-[(2-iodophenyl)methyl]-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-42-3P, N-[(2-Bromophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-
 pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-43-4P, 1-Ethyl-N-[[4-(hydroxymethyl)phenyl]methyl]-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-44-5P, 1-Ethyl-N-[[3-(hydroxymethyl)phenyl]methyl]-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-45-6P, 1-Ethyl-N-[[3-(hydroxymethyl)-2-methylphenyl]methyl]-
 4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675119-46-7P, N-[[2,3-Dichloro-6-
 (hydroxymethyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-
 1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-47-8P,
 N-[(2,4-Dichloro-6-methylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-48-9P,
 1-Ethyl-N-[[4-(2-methylpropyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-49-0P,
 N-[(2,5-Dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-
 1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-50-3P,
 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(2,4,5-
 trifluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-51-4P, 1-Ethyl-N-[[2-fluoro-4-(trifluoromethyl)phenyl]methy
 l]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675119-52-5P, N-[(2-Chloro-6-methylphenyl)methyl]-1-
 ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675119-53-6P, 4-[[[1-Ethyl-4-[(tetrahydro-2H-pyran-
 4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]benzoic
 acid sodium salt 675119-54-7P, 3-[[[1-Ethyl-4-[(tetrahydro-2H-
 pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-
 yl]carbonyl]amino]methyl]benzoic acid 675119-57-0P,
 N-[[4-(Dimethylamino)phenyl]methyl]-1-ethyl-4-[[4-
 (hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-58-1P, 1-Ethyl-4-[[4-[(ethyloxy)imino]cyclohexyl]amino]-N-
 [[4-(methyloxy)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-59-2P, 1-Ethyl-4-[[4-[(methyloxy)imino]cyclohexyl]amino]-N-
 [[4-(methyloxy)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675119-60-5P, 4-[[4-[[1,1-Dimethylethyl]oxy]imino]cyclohexyl]amin
 o]-1-ethyl-N-[[4-(methyloxy)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675119-61-6P, 1-Ethyl-N-[[4-
 (methyloxy)phenyl]methyl]-4-[(7-oxohexahydro-1H-azepin-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675119-64-9P,
 4-[(trans-4-Aminocyclohexyl)amino]-1-ethyl-N-(phenylmethyl)-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675119-65-0P,
 4-[(trans-2-Aminocyclohexyl)amino]-1-ethyl-N-(phenylmethyl)-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675119-66-1P,
 4-[(cis-2-Aminocyclohexyl)amino]-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-
 b]pyridine-5-carboxamide 675119-67-2P, 4-[(3-
 Aminocyclohexyl)amino]-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-
 5-carboxamide 675119-72-9P 675119-73-0P
 675119-74-1P 675119-77-4P 675119-78-5P
 675119-79-6P 675119-80-9P, N-[(2,3-
 Dichlorophenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-
 b]pyridine-5-carboxamide 675119-83-2P, N-[(2,4-
 Dimethylphenyl)methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675119-84-3P,
 N-[(3,4-Dimethylphenyl)methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amin
 o]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-85-4P,
 N-[(2,3-Dichlorophenyl)methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amin

o]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-86-5P,
 N-[(3-Chloro-4-methylphenyl)methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-87-6P, N-[(4-Chloro-2-methylphenyl)methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-88-7P, N-[[4-[(Difluoromethyl)oxy]phenyl]methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-89-8P, 1-Ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[[4-(trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-93-4P,
 N-[(3,4-Dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide hydrochloride (1:1)
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE4 inhibitor; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic disease)


RN 675119-13-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(difluoromethoxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-14-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-[(dimethylamino)methyl]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-15-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3-chloro-4-methoxyphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-17-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 675119-19-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-[(acetylamino)methyl]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-20-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-fluorophenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-21-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-22-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[2-ethylphenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-23-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-24-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(2,3,4-trifluorophenyl)methyl]- (CA INDEX NAME)




RN 675119-25-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-chloro-2-fluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-26-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-bromo-2-fluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-27-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,5-dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-28-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,3-dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-29-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,3-dichlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-30-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-cyanophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675119-31-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-bromophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-32-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[5-fluoro-2-(trifluoromethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-33-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-iodophenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-34-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(1,1-dimethylethyl)phenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-35-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3-cyanophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-36-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,6-dichlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-37-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(5-chloro-2-methylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-38-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,5-dibromophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-39-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-ethylphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-40-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-41-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2-iodophenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-42-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-bromophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-43-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-(hydroxymethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-44-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[3-(hydroxymethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-45-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[3-(hydroxymethyl)-2-methylphenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-46-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[2,3-dichloro-6-(hydroxymethyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-47-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-dichloro-6-methylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-48-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-(2-methylpropyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-49-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,5-dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-50-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(2,4,5-trifluorophenyl)methyl]- (CA INDEX NAME)




RN 675119-51-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-52-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-chloro-6-methylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675119-53-6 CAPLUS


CN Benzoic acid, 4-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 675119-54-7 CAPLUS

CN Benzoic acid, 3-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]- (CA INDEX NAME)



RN 675119-57-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(dimethylamino)phenyl]methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)



RN 675119-58-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(ethoxyimino)cyclohexyl]amino]-1-ethyl-N-[[4-methoxyphenyl]methyl]- (CA INDEX NAME)

INDEX NAME)




RN 675119-59-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(methoxyimino)cyclohexyl]amino]-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 675119-60-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-[(1,1-dimethylethoxy)imino]cyclohexyl]amino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 675119-61-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(hexahydro-7-oxo-1H-azepin-4-yl)amino]-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 675119-64-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(trans-4-aminocyclohexyl)amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 675119-65-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1R,2R)-2-aminocyclohexyl]amino]-1-ethyl-N-(phenylmethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 675119-66-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(1R,2S)-2-aminocyclohexyl]amino]-1-ethyl-N-(phenylmethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 675119-67-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(3-aminocyclohexyl)amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)



RN 675119-72-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-fluorophenyl)methyl]-4-[[(1R,3S)-3-hydroxycyclohexyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 675119-73-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[(1R,3S)-3-hydroxycyclohexyl]amino]-N-[[4-(methanesulfonyl)phenyl]methyl]-, rel- (CA INDEX NAME).


Relative stereochemistry.



RN 675119-74-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethoxyphenyl)methyl]-1-ethyl-4-[[(1R,3S)-3-hydroxycyclohexyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 675119-77-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethylphenyl)methyl]-1-ethyl-4-[[[(1R,3S)-3-hydroxycyclohexyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 675119-78-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[[(1R,3S)-3-hydroxycyclohexyl]amino]-N-[(4-methoxyphenyl)methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 675119-79-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-dimethylphenyl)methyl]-1-ethyl-4-[(1R,3S)-3-hydroxycyclohexyl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.






RN 675119-80-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,3-dichlorophenyl)methyl]-1-ethyl-4-[(4R,6S)-4-hydroxycyclohexyl]amino]-, rel- (CA INDEX NAME)



RN 675119-83-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-dimethylphenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)






RN 675119-87-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-chloro-2-methylphenyl)methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 675119-88-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(difluoromethoxy)phenyl]methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 675119-89-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[[4-(trifluoromethyl)phenyl]methyl]-
(CA INDEX NAME)



RN 675119-93-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 675112-50-2P, N-Benzyl-4-(cyclohexylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675112-75-1P, N-Benzyl-4-[[1-[[1,1-dimethylethyl]oxy]carbonyl]-4-piperidinyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic disease)


RN 675112-50-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-(phenylmethyl)- (CA INDEX NAME)



RN 675112-75-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-ethyl-5-[[[(phenylmethyl)amino]carbonyl]-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



L4 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:190924 CAPLUS

DOCUMENT NUMBER: 132:237088

TITLE: Preparation of fused pyridine inhibitors of cGMP phosphodiesterase

INVENTOR(S): Macor, John E.; Yu, Guixue

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000015222	A1	20000323	WO 1999-US21070	19990913
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,				



ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6326379	B1	20011204	US 1999-393833	19990910
CA 2342583	A1	20000323	CA 1999-2342583	19990913
AU 9961438	A1	20000403	AU 1999-61438	19990913
AU 751486	B2	20020815		
EP 1113796	A1	20010711	EP 1999-948211	19990913

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: US 1998-100665P P 19980916
 WO 1999-US21070 W 19990913

OTHER SOURCE(S): MARPAT 132:237088
 GI



AB The title compds. [I or II; E1 = OR1, SR1, NH-Al-cycloalkyl, etc.; E2 = NH-Al-alkoxy, NH-Al-CO2alkyl, NH-Al-aryl, etc.; R1 = Al-cycloalkyl, Al-alkoxy, Al-aryl, etc.; X1 = OA1R2, OR9, NR9R10, etc.; X2 = OA1R25, N(R5)A2R25, etc.; X3 = OR9, OA1OR9, NR9R10, etc.; A1 = (un)substituted alkylene; Y = N, CR6; Z = N, CR7 with the proviso that at least one of Y and Z = N; R3 = H, alkyl, cycloalkyl, etc.; R6, R7 = H, alkyl, cycloalkyl, etc.; R4 = H, 1- or 3-imidazolyl, etc.; A2 = a direct bond, alkylene, alkenyl, etc.; R2 = cycloalkyl, aryl, heteroaryl, etc.; R25 = cycloalkyl, aryl, heteroaryl, etc.; R5 = H, alkyl, cycloalkyl, etc.; R9, R10 = H, alkyl, cycloalkyl, etc.], useful for treating a cGMP PDE (especially type V) associated condition such as erectile dysfunction, were prepared Thus, reacting 4-([(3-chloro-4-methoxyphenyl)methyl]amino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid with 4-aminomethylpyridine in the presence of EDAC.HCl, 1-hydroxybenzotriazole and Et3N in THF afforded 90% II [Y = N; Z = CH; E2 = 3-Cl-4-MeOC6H3CH2NH; X2 = 4-pyridinylmethylamino; R3 = Et; R4 = H]. Compds. I are effective at 0.05-100 mg/kg/day.


IT 261769-48-6P 261769-53-3P 261769-57-7P
 261769-59-9P 261769-65-7P 261769-66-8P
 261769-81-7P 261769-83-9P 261769-88-4P
 261770-38-1P 261770-45-0P 261770-54-1P
 261770-55-2P 261770-58-5P 261770-60-9P
 261770-74-5P 261770-77-8P 261770-90-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of fused pyridine inhibitors of cGMP phosphodiesterase)

RN 261769-48-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-([(1R)-1-cyclohexylethyl]amino)-1-ethyl-N-[(4-hydroxy-3-methoxyphenyl)methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 261769-53-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-chlorophenyl)methyl]-4-[[[(1R)-1-cyclohexylethyl]amino]-1-ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 261769-57-7 CAPLUS


CN Benzeneacetic acid, α -[[[4-[[[(1R)-1-cyclohexylethyl]amino]-1-ethyl]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-, ethyl ester, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 261769-59-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1R)-1-cyclohexylethyl]amino]-1-ethyl-N-[[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 261769-65-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1R)-1-cyclohexylethyl]amino]-N-[(2,6-difluorophenyl)methyl]-1-ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 261769-66-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1R)-1-cyclohexylethyl]amino]-1-ethyl-N-(phenylmethyl)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 261769-81-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(1R)-1-cyclohexylethyl]amino]-N-[(2,4-dimethoxyphenyl)methyl]-1-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 261769-83-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(1R)-1-cyclohexylethyl]amino]-N-[(3,4-difluorophenyl)methyl]-1-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 261769-88-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(1R)-1-cyclohexylethyl]amino]-1-ethyl-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 261770-38-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(1R)-1-cyclohexylethyl]amino]-1-ethyl-N-[1-(4-hydroxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 261770-45-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1-cyclohexylethyl]amino]-1-ethyl-N-[(4-hydroxy-3-methoxyphenyl)methyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 261770-54-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-1-ethyl-N-[(3-hydroxy-4-methoxyphenyl)methyl]-
(9CI) (CA INDEX NAME)




RN 261770-55-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-1-ethyl-N-[[4-(1,2,3-thiadiazol-4-yl)phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 261770-58-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[[3-chloro-4-methoxyphenyl)methyl]-4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-1-ethyl- (9CI) (CA INDEX NAME)



RN 261770-60-9 CAPLUS


CN Benzeneacetic acid, α -[[[4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-, ethyl ester, (α R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 261770-74-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-[[4-(dimethylamino)phenyl]methyl]-1-ethyl-(9CI) (CA INDEX NAME)



RN 261770-77-8 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-1-ethyl-N-[[4-fluoro-2-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 261770-90-5 CAPLUS

CN Benzeneacetic acid, α-[[[4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-4-hydroxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:614428 CAPLUS

DOCUMENT NUMBER: 111:214428

TITLE: Synthesis and structure-activity relationships of a series of anxiolytic pyrazolopyridine ester and amide anxiolytic agents

AUTHOR(S): Bare, Thomas M.; McLaren, Charles D.; Campbell, James B.; Firor, Judy W.; Resch, James F.; Walters, Claudia P.; Salama, Andre I.; Meiners, Brad A.; Patel, Jitendra B.

CORPORATE SOURCE: Dep. Med. Chem., ICI Americas Inc., Wilmington, DE, 19897, USA


SOURCE: Journal of Medicinal Chemistry (1989), 32(12), 2561-73
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 111:214428

GI



I

AB A series of 1-substituted 4-amino-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid esters and amides, e.g., I, were synthesized and screened for anxiolytic activity in the shock-induced suppression of drinking (SSD) test. The compds. were also tested for their ability to displace [3H]flunitrazepam (FLU) from brain benzodiazepine (BZ) binding sites. Many compds. were active in these screens and, addnl., demonstrated a selectivity for the type 1 BZ (BZ1) receptor over the type 2 BZ (BZ2) receptor as indicated by Hill coeffs. significantly less than unity and by anal. of [3H]FLU binding results from different brain regions. Based on the results of structure activity studies of these compds., a hypothesis was proposed to explain the structural features necessary for optimal

interaction with brain B2 receptors. A detailed pharmacol. evaluation showed that I is the most potent behaviorally active compound and demonstrated it to be BZ1 selective; also, in comparison to diazepam, I showed minimal sedative and alc. interactive properties at therapeutically EDs.


IT 103585-88-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and anxiolytic activity of)

RN 103585-88-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-amino-1-pentyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1986:478930 CAPLUS

DOCUMENT NUMBER: 105:78930

TITLE: 1H-pyrazolo[3,4-b]pyridinecarboxamides

INVENTOR(S): Bare, Thomas Michael

PATENT ASSIGNEE(S): ICI Americas, Inc., USA

SOURCE: Eur. Pat. Appl., 47 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 180318	A1	19860507	EP 1985-306798	19850924
EP 180318	B1	19911106		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4745121	A	19880517	US 1985-774905	19850911
ZA 8507173	A	19860730	ZA 1985-7173	19850918
AU 8547597	A	19860410	AU 1985-47597	19850919
AU 573899	B2	19880623		
IL 76427	A	19891215	IL 1985-76427	19850919
AT 69228	T	19911115	AT 1985-306798	19850924
CN 85107874	A	19860730	CN 1985-107874	19850926
HU 38344	A2	19860528	HU 1985-3823	19851002
NO 8503923	A	19860407	NO 1985-3923	19851003
DK 8504546	A	19860405	DK 1985-4546	19851004
FI 8503859	A	19860405	FI 1985-3859	19851004
JP 61091188	A	19860509	JP 1985-220499	19851004
ES 547620	A1	19870216	ES 1985-547620	19851004
PRIORITY APPLN. INFO.:			GB 1984-25104	A 19841004
			EP 1985-306798	A 19850924

OTHER SOURCE(S): MARPAT 105:78930

GI




AB The title compds. [I; R1 = alkenyl, alkynyl, cyanoalkyl, ketoalkyl, (halo)alkyl; R2 = H, alkyl, alkanoyl; R3, R4 = H, cycloalkyl, cycloalkylalkyl, alkynyl, alkoxy, thiazolyl, Ph, PhCH2, (un)substituted alkyl; R3R4N = heterocyclyl] and the 7-N-oxides thereof were prepared as tranquilizers (no data). Thus, pyrazolo[3,4-b]pyridine II (R5 = Cl, R6 = CO2Et) was aminated with liquid NH3 and saponified to give 81% II (R5 = NH2, R6 = CO2H). This was converted to the acid chloride and amidated with PrNH2 to give 72% I (R1 = pentyl, R2 = R3 = H, R4 = Pr).

IT 103585-88-2P
 RL: SPN (Synthetic preparation); PREP. (Preparation)
 (preparation of, as tranquilizer)

RN 103585-88-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-amino-1-pentyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1978:190885 CAPLUS

DOCUMENT NUMBER: 88:190885

TITLE: 3,7-Dihydro- and 1,7-dihydro-4H-pyrazolo[4',3':5,6]-pyrido[4,3-d]pyrimidin-4-ones

INVENTOR(S): Denzel, Theodor; Hoehn, Hans

PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc., USA

SOURCE: U.S., 7 pp.
 CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO..	KIND	DATE	APPLICATION NO.	DATE
US 4072681	A	19780207	US 1977-773562	19770302
CA 1091667	A1	19801216	CA 1978-296875	19780215
GB 1597091	A	19810903	GB 1978-6858	19780221
DE 2809033	A1	19780907	DE 1978-2809033	19780302
JP 53109000	A	19780922	JP 1978-24360	19780302
FR 2382452	A1	19780929	FR 1978-6020	19780302
FR 2382452	B1	19801219		
PRIORITY APPLN. INFO.:			US 1977-773562	A 19770302

OTHER SOURCE(S):
GI

MARPAT 88:190885




AB The title compds. I and II (R = H, lower alkyl, phenyl; R1, R3, R4 = H, lower alkyl; R2 = H, lower alkyl, Ph, Ph substituted by 1 or 2 halo, lower alkyl, lower alkoxy, phenyl-lower alkyl, di(lower alkyl)amino-lower alkyl) were prepared. Thus, 4-amino-1-ethylpyrazolo[3,4-b]pyridine-5-carboxylic acid was aminated with SOCl₂ and NH₃ followed by cyclization with HC(OEt)₃ to give II (R = Et, R1-R4 = H). At 10-50 mg/kg/day I and II were antiinflammatory and at 10-15 mg/kg/day had central nervous system depressant activity.

IT 66373-07-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cyclization with formic acid)

RN 66373-07-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-amino-1-ethyl-N-(phenylmethyl)-
(9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 09:20:50 ON 17 OCT 2007)

FILE 'REGISTRY' ENTERED AT 09:20:59 ON 17 OCT 2007

L1 STRUCTURE UPLOADED
L2 42 S L1
L3 907 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:22:09 ON 17 OCT 2007

L4 14 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

76.60

249.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

CA SUBSCRIBER PRICE

ENTRY	SESSION
-10.92	-10.92

STN INTERNATIONAL LOGOFF AT 09:25:37 ON 17 OCT 2007